

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 February 2003 (20.02.2003)

PCT

(10) International Publication Number
WO 03/014092 A1

(51) International Patent Classification⁷: **C07D 239/42**,
403/14, 409/12, 401/12, 405/12, 405/14, 401/14, 409/14,
401/14, A61K 31/506, A61P 19/02

(21) International Application Number: PCT/SE02/01437

(22) International Filing Date: 8 August 2002 (08.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0119472.9 9 August 2001 (09.08.2001) GB

(71) Applicant (for all designated States except US): **AS-TRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FINLAY, Raymond** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **WATERSON, David** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,

SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW; ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS



(57) Abstract: Compounds of the formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.



WO 03/014092 A1

ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS

COMPOUNDS

The present invention relates to compounds useful in the inhibition of metalloproteinases and in particular to pharmaceutical compositions comprising these, as well as their use. In particular, the compounds of this invention are inhibitors of matrix metalloproteinase 13 (MMP13), known also as collagenase 3.

Metalloproteinases are a superfamily of proteinases (enzymes) whose numbers in recent years have increased dramatically. Based on structural and functional considerations these enzymes have been classified into families and subfamilies as described in N.M. Hooper (1994) FEBS Letters 354:1-6. Examples of metalloproteinases include the matrix metalloproteinases (MMPs); the reprolysin or adamalysin or MDC family which includes the secretases and sheddases such as TNF converting enzymes (ADAM10 and TACE); the astacin family which include enzymes such as procollagen processing proteinase (PCP); and other metalloproteinases such as aggrecanase, the endothelin converting enzyme family and the angiotensin converting enzyme family.

Metalloproteinases are believed to be important in a plethora of physiological disease processes that involve tissue remodelling such as embryonic development, bone formation and uterine remodelling during menstruation. This is based on the ability of the metalloproteinases to cleave a broad range of matrix substrates such as collagen, proteoglycan and fibronectin. Metalloproteinases are also believed to be important in the processing, or secretion, of biological important cell mediators, such as tumour necrosis factor (TNF); and the post translational proteolysis processing, or shedding, of biologically important membrane proteins, such as the low affinity IgE receptor CD23 (for a more complete list see N. M. Hooper *et al.*, (1997) Biochem J. 321:265-279).

Metalloproteinases have been associated with many disease conditions. Inhibition of the activity of one or more metalloproteinases may well be of benefit in these disease conditions, for example: various inflammatory and allergic diseases such as, inflammation of the joint (especially rheumatoid arthritis, osteoarthritis and gout), inflammation of the gastro-intestinal tract (especially inflammatory bowel disease, ulcerative colitis and gastritis), inflammation of the skin (especially psoriasis, eczema, dermatitis); in tumour metastasis or invasion; in disease associated with uncontrolled degradation of the

extracellular matrix such as osteoarthritis; in bone resorptive disease (such as osteoporosis and Paget's disease); in diseases associated with aberrant angiogenesis; the enhanced collagen remodelling associated with diabetes, periodontal disease (such as gingivitis), corneal ulceration, ulceration of the skin, post-operative conditions (such as colonic anastomosis) and dermal wound healing; demyelinating diseases of the central and peripheral nervous systems (such as multiple sclerosis); Alzheimer's disease; extracellular matrix remodelling observed in cardiovascular diseases such as restenosis and atherosclerosis; and chronic obstructive pulmonary diseases, COPD (for example, the role of MMPs such as MMP12 is discussed in Anderson & Shinagawa, 1999, Current Opinion in Anti-inflammatory and Immunomodulatory Investigational Drugs, 1(1): 29-38).

The matrix metalloproteinases (MMPs) are a family of structurally-related zinc-containing endopeptidases which mediate the breakdown of connective tissue macromolecules. The mammalian MMP family is composed of at least twenty enzymes, classically divided into four sub-groups based on substrate specificity and domain structure [Alexander & Werb (1991) in Hay, E.D. ed. "Cell Biology of the Extracellular Matrix", New York, Plenum Press, 255-302; Murphy & Reynolds (1993) in Royce, P.M. & Steinman, B. eds. "Connective Tissue and its Heritable Disorders", New York, Wiley-Liss Inc., 287-316; Birkedal-Hansen (1995) Curr. Opin. Cell Biol. 7:728-735]. The sub-groups are the collagenases (such as MMP1, MMP8, MMP13), the stromelysins (such as MMP3, MMP10, MMP11), the gelatinases (such as MMP2, MMP9) and the membrane-type MMPs (such as MMP14, MMP15, MMP16, MMP17). Enzyme activity is normally regulated *in vivo* by tissue inhibitors of metalloproteinases (TIMPs).

Because of their central role in re-modelling connective tissue, both as part of normal physiological growth and repair and as part of disease processes, there has been substantial interest in these proteins as targets for therapeutic intervention in a wide range of degenerative and inflammatory diseases, such as arthritis, atherosclerosis, and cancer [Whittaker *et al* (1999) Chem. Rev. 99:2735-2776].

A number of MMP inhibitor compounds are known and some are being developed for pharmaceutical uses (see for example the review by Beckett & Whittaker (1998) Exp. Opin. Ther. Patents, 8(3):259-282). Different classes of compounds may have different degrees of potency and selectivity for inhibiting various MMPs. Whittaker M. *et al* (1999,

Chem. Rev. 99:2735-2776) review a wide range of known MMP inhibitor compounds. They state that an effective MMP inhibitor requires a zinc binding group or ZBG (functional group capable of chelating the active site zinc(II) ion), at least one functional group which provides a hydrogen bond interaction with the enzyme backbone, and one or
5 more side chains which undergo effective van der Waals interactions with the enzyme subsites. Zinc binding groups in known MMP inhibitors include hydroxamic acids (-C(O)NHOH), reverse hydroxamates (-N(OH)CHO), thiols, carboxylates and phosphonic acids.

We have discovered a new class of compounds that are inhibitors of
10 metalloproteinases and are of particular interest in inhibiting MMP13. The compounds of this invention have beneficial potency and/or pharmacokinetic properties. In particular they show selectivity for MMP13.

MMP13, or collagenase 3, was initially cloned from a cDNA library derived from a breast tumour [J. M. P. Freije *et al.* (1994) Journal of Biological Chemistry 269(24):16766-
15 16773]. PCR-RNA analysis of RNAs from a wide range of tissues indicated that MMP13 expression was limited to breast carcinomas as it was not found in breast fibroadenomas, normal or resting mammary gland, placenta, liver, ovary, uterus, prostate or parotid gland or in breast cancer cell lines (T47-D, MCF-7 and ZR75-1). Subsequent to this observation MMP13 has been detected in transformed epidermal keratinocytes [N. Johansson *et al.*,
20 (1997) Cell Growth Differ. 8(2):243-250], squamous cell carcinomas [N. Johansson *et al.*, (1997) Am. J. Pathol. 151(2):499-508] and epidermal tumours [K. Airola *et al.*, (1997) J. Invest. Dermatol. 109(2):225-231]. These results are suggestive that MMP13 is secreted by transformed epithelial cells and may be involved in the extracellular matrix degradation and cell-matrix interaction associated with metastasis especially as observed in invasive
25 breast cancer lesions and in malignant epithelia growth in skin carcinogenesis.

Recent published data implies that MMP13 plays a role in the turnover of other connective tissues. For instance, consistent with MMP13's substrate specificity and preference for degrading type II collagen [P. G. Mitchell *et al.*, (1996) J. Clin. Invest. 97(3):761-768; V. Knauper *et al.*, (1996) The Biochemical Journal 271:1544-1550],
30 MMP13 has been hypothesised to serve a role during primary ossification and skeletal remodelling [M. Stahle-Backdahl *et al.*, (1997) Lab. Invest. 76(5):717-728; N. Johansson


et al., (1997) Dev. Dyn. 208(3):387-397], in destructive joint diseases such as rheumatoid and osteo-arthritis [D. Wernicke *et al.*, (1996) J. Rheumatol. 23:590-595; P. G. Mitchell *et al.*, (1996) J. Clin. Invest. 97(3):761-768; O. Lindy *et al.*, (1997) Arthritis Rheum 40(8):1391-1399]; and during the aseptic loosening of hip replacements [S. Imai *et al.*, (1998) J. Bone Joint Surg. Br. 80(4):701-710]. MMP13 has also been implicated in chronic adult periodontitis as it has been localised to the epithelium of chronically inflamed mucosa human gingival tissue [V. J. Uitto *et al.*, (1998) Am. J. Pathol 152(6):1489-1499] and in remodelling of the collagenous matrix in chronic wounds [M. Vaalamo *et al.*, (1997) J. Invest. Dermatol. 109(1):96-101].

US 6100266 and WO-99/38843 disclose compounds of the general formula



for use in the manufacture of a medicament for the treatment or prevention of a condition associated with matrix metalloproteinases. Specifically disclosed is the compound N-{1S-[4-(4-Chlorophenyl) piperazine-1-sulfonylmethyl]-2-methylpropyl}-N-hydroxyformamide.


WO-01/87870 discloses hydroxamic acid derivatives of the general formula



wherein D and B are each an aryl or heteroaryl ring and A is a heterocyclic ring, for use as inhibitors of matrix metalloproteinases.


WO-00/12478 discloses arylpiperazines that are matrix metalloproteinase inhibitors, including compounds with an hydroxamic acid zinc binding group and compounds with a reverse hydroxamate zinc binding group.

WO-2000/51993 claims dihetero-substituted metalloprotease inhibitors, including a compound of the formula:



We have now discovered compounds that are potent MMP13 inhibitors and have desirable activity profiles.

In a first aspect of the invention we now provide a compound of the formula I



wherein

A and **B** are each independently selected from phenyl and up to C6 heteroaryl;
at least one of **A** and **B** is heteroaryl;

n1 and **n2** are each independently selected from 0, 1, 2, 3;

each **R2** and each **R3** is independently selected from OH, NO₂, CF₃, CN, halogen,
SC₁₋₄alkyl, SOC₁₋₄alkyl, SO₂C₁₋₄alkyl, C₁₋₄alkyl, C₁₋₄alkoxy;

M₁ is selected from N and C;

R1 is the group -X-Y;

X is C₁₋₆alkyl;

Y is selected from up to C10 cycloalkyl, up to C10 aryl, and up to C10 heteroaryl;

Y is optionally substituted by up to three groups independently selected from OH,

NO₂, CF₃, CN, halogen, SC₁₋₄alkyl, SOC₁₋₄alkyl, SO₂C₁₋₄alkyl, C₁₋₄alkyl, C₁₋₄alkoxy;

Z is selected from -N(OH)CHO, and -C(O)NHOH;

Any heteroaryl group outlined above is an aromatic ring containing one or more
heteroatoms independently selected from N, O, S;

Any alkyl group outlined above may be straight chain or branched.

Preferred compounds of the formula I are those wherein any one or more of the
following apply:

at least one of **A** and **B** is a five- or six-membered aromatic ring containing one or
more heteroatoms independently selected from N, O, S; preferably at least one of **A** and **B**
is pyridyl, pyrimidinyl, thienyl, furyl;

B is not substituted or is substituted by at least one **R2** group selected from CF₃, CN,
halogen (preferably fluoro or chloro), C₁₋₄alkyl;

A is not substituted or is substituted by at least one **R3** group selected from CF₃, CN, halogen (preferably fluoro or chloro), C₁₋₄alkyl;

M₁ is N;

X is C₂₋₅alkyl; preferably **X** is C₂₋₃alkyl;

5 **Y** is selected from phenyl and a five- or six-membered aromatic ring containing one or more heteroatoms independently selected from N, O, S; preferably **Y** is phenyl, pyridyl, pyrimidinyl, or pyrazinyl; most preferably **Y** is pyrimidinyl;

Y is not substituted or is substituted by at least one group independently selected from halogen (preferably fluoro or chloro), CF₃, or MeO; preferably **Y** is not substituted or is substituted by at least one halogen group (preferably fluoro or chloro);

10 **Z** is -N(OH)CHO.

For example, preferred compounds of the invention include those wherein **B** is heteroaryl (preferably pyridyl, pyrimidinyl, thienyl, furyl; most preferably pyridyl) and **A** is phenyl.


15 Other preferred compounds of the invention include those wherein **B** is phenyl or heteroaryl (preferably pyridyl, pyrimidinyl, thienyl, furyl; most preferably pyridyl) and **A** is heteroaryl (preferably pyridyl or pyrimidinyl; most preferably pyrimidinyl).

Other preferred compounds include those wherein **R1** is 3- or 4- chlorophenylethyl, 3- or 4- chlorophenylpropyl, 2- or 3-pyridylethyl, 2- or 3-pyridylpropyl, 2- or 4-pyrimidinylethyl (optionally monosubstituted by fluoro or chloro), 2- or 4-pyrimidinylpropyl (optionally monosubstituted by fluoro or chloro), 2-(2-pyrimidinyl)ethyl (optionally monosubstituted by fluoro or chloro), 2-(2-pyrimidinyl)propyl (optionally monosubstituted by fluoro or chloro). Particularly preferred compounds include those

20 wherein **R1** is 2-pyrimidinylpropyl, 2-pyrimidinylethyl, and 5-fluoro-2-pyrimidinylethyl.

25

Particularly preferred compounds of the invention are compounds of the formula II, wherein Z is a reverse hydroxamate group:



wherein A, B, n1, n2, M1, R1, R2, R3, X and Y are as defined above for the compound of formula I.

It will be appreciated that the particular substituents and number of substituents on A and/or B and/or R1 are selected so as to avoid sterically undesirable combinations.

Each exemplified compound represents a particular and independent aspect of the invention.

Where optically active centres exist in the compounds of formula I, we disclose all individual optically active forms and combinations of these as individual specific embodiments of the invention, as well as their corresponding racemates.

It will be appreciated that the compounds according to the invention can contain one or more asymmetrically substituted carbon atoms. The presence of one or more of these asymmetric centres (chiral centres) in a compound of formula I can give rise to stereoisomers, and in each case the invention is to be understood to extend to all such stereoisomers, including enantiomers and diastereomers, and mixtures including racemic mixtures thereof.

Where tautomers exist in the compounds of formula I, we disclose all individual tautomeric forms and combinations of these as individual specific embodiments of the invention.

As previously outlined the compounds of the invention are metalloproteinase inhibitors, in particular they are inhibitors of MMP13. Each of the above indications for the compounds of the formula I represents an independent and particular embodiment of the invention. Whilst we do not wish to be bound by theoretical considerations, the compounds of the invention are believed to show selective inhibition for any one of the

above indications relative to any MMP1 inhibitory activity, by way of non-limiting example they may show 100-1000 fold selectivity over any MMP1 inhibitory activity.

The compounds of the invention may be provided as pharmaceutically acceptable salts. These include acid addition salts such as hydrochloride, hydrobromide, citrate and maleate salts and salts formed with phosphoric and sulphuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, or organic amine salt for example triethylamine.

They may also be provided as *in vivo* hydrolysable esters. These are pharmaceutically acceptable esters that hydrolyse in the human body to produce the parent compound. Such esters can be identified by administering, for example intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluids. Suitable *in vivo* hydrolysable esters for carboxy include methoxymethyl and for hydroxy include formyl and acetyl, especially acetyl.

In order to use a compound of the formula I or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula I or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester and pharmaceutically acceptable carrier.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, topical, parenteral, buccal, nasal, vaginal or rectal administration or by inhalation. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.

In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially)

with, one or more pharmacological agents of value in treating one or more disease conditions referred to hereinabove.

The pharmaceutical compositions of this invention will normally be administered to humans so that, for example, a daily dose of 0.5 to 75 mg/kg body weight (and preferably
5 of 0.5 to 30 mg/kg body weight) is received. This daily dose may be given in divided doses as necessary, the precise amount of the compound received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease condition being treated according to principles known in the art.

Typically unit dosage forms will contain about 1 mg to 500 mg of a compound of this
10 invention.





Therefore in a further aspect, the present invention provides a compound of the formula I or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof for use in a method of therapeutic treatment of the human or animal body. In particular we disclose use in the treatment of a disease or condition mediated by MMP13.

In yet a further aspect the present invention provides a method of treating a
15 metalloproteinase mediated disease condition which comprises administering to a warm-blooded animal a therapeutically effective amount of a compound of the formula I or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof. Metalloproteinase mediated disease conditions include arthritis (such as osteoarthritis), atherosclerosis,
20 chronic obstructive pulmonary diseases (COPD).





In another aspect the present invention provides processes for preparing a compound of the formula I or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof which processes are described below.

25 Where Z is N(OH)CHO, a compound of the formula II is prepared from a compound of the formula III by addition of hydroxylamine followed by formylation. The compound of formula III is prepared conveniently from a compound of the formula IV and a compound of the formula V by cross-coupling methodology where A₁ and B₁ are groups
30 that enable the coupling to occur.

10




A compound of the formula IV is conveniently prepared by reaction of the
 5 sulphonamide of the formula VI with an aldehyde of the formula VIII or with an alkyl or
 aryl ester of the formula IX. A compound of the formula VI is prepared from a compound
 of the formula VII.



10



15

A compound of the formula VII is conveniently prepared from a compound of the formula XI (where P is hydrogen or a suitable protecting group and M_1' is hydrogen or a suitably reactive group) and a compound of the formula X (where A_2 is a group to enable reaction of X and XI)



To those skilled in the art it will be clear that ring B could be incorporated into a compound of the formula II at alternative stages of the synthesis.


10 Where Z is C(O)NHOH, a compound of the formula XII is conveniently prepared from a precursor carboxylic acid (compound of the formula XIII)




A compound of the formula XIII is prepared from a compound of the formula IV and a compound of the formula XV by cross-coupling methodology where A_1 and B_1 are groups that enable the coupling to occur.

20

12



A compound of the formula XV is prepared from compounds of the formulae VI and XVI, where X is a suitable leaving group.



To those skilled in the art it will be clear that ring B could be incorporated into compound XII at alternative stages of the synthesis.

It will be appreciated that many of the relevant starting materials are commercially available or may be made by any convenient method as described in the literature or known to the skilled chemist or described in the Examples herein. In addition the following table shows details of intermediates and their corresponding registry numbers in Chemical Abstracts.

Chemical Abstracts Registry Numbers

4-Pyridylboronic acid	1692-15-5
3-Pyridylboronic acid	1692-25-7
2-Thiophenboronic acid	6165-68-0
3-Thiophenboronic acid	6165-69-1
4-Methyl 2-thiophenboronic acid	162607-15-0
3-Furanboronic acid	55552-70-0
5-Pyrimidine butanal	260441-11-0
Piperazine, 1-(5-bromo-2-pyridinyl)-4-(methylsulfonyl)	260441-55-2
4-Fluorophenyl boronic acid	1765-93-1

Chemical Abstracts Registry Numbers

4-Chlorophenyl boronic acid	1679-18-1
2-(tri-n-butylstannyl)pyridine	17997-47-6
2-(tri-n-butylstannyl)thiophene	54663-78-4
2-(tri-n-butylstannyl)furan	118486-94-5
2-Chlorophenyl boronic acid	3900-89-8
4-Ethoxyphenyl boronic acid	22237-13-4
4-(Methylthio)phenyl boronic acid	98546-51-1
2-(Trifluoromethyl)Phenylboronic Acid	1423-27-4
2,4-Difluorophenylboronic Acid	144025-03-6
2-Bromophenylboronic Acid	98437-24-2
2-Fluorophenyl boronic acid	1993-03-9
4-Pyrimidin-2-yl butanal	260441-10-9
3-(5-Chloropyrimidin-2-yl)propanal	357647-90-6
3-(5-Fluoropyrimidin-2-yl)propanal	357647-69-9
3-Pyrimidin-2-yl propanal	260441-07-4
3,4-Difluorophenyl boronic acid	168267-41-2
Pyrimidin-5-yl boronic acid	109299-78-7
2,4-Dimethoxy-5-pyrimidinyl boronic acid	89641-18-9
3,5-Difluorophenyl boronic acid	156545-07-02
2-Methoxyphenyl boronic acid	5720-06-9
4-Trifluoromethylphenyl boronic acid	128796-39-4
3-Fluorophenyl boronic acid	768-35-4
4-Methoxyphenyl boronic acid	5720-07-0
2-Furanboronic acid	13331-23-2
3-Trifluoromethyl boronic acid	1423-26-3
3-Chlorophenyl boronic acid	63503-60-6
3-Cyanophenyl boronic acid	150255-96-2
2-Chloro-4-fluorophenylzinc iodide (0.5M in THF)	Rieke Metals, Inc

The compounds of the invention may be evaluated for example in the following assays:

Isolated Enzyme Assays

Matrix Metalloproteinase family including for example MMP13.

Recombinant human proMMP13 may be expressed and purified as described by Knauper *et al.* [V. Knauper *et al.*, (1996) The Biochemical Journal 271:1544-1550 (1996)]. The purified enzyme can be used to monitor inhibitors of activity as follows: purified proMMP13 is activated using 1mM amino phenyl mercuric acid (APMA), 20 hours at 21°C; the activated MMP13 (11.25ng per assay) is incubated for 4-5 hours at 35°C in assay buffer (0.1M Tris-HCl, pH 7.5 containing 0.1M NaCl, 20mM CaCl₂, 0.02 mM ZnCl₂ and 0.05% (w/v) Brij 35 using the synthetic substrate 7-methoxycoumarin-4-yl)acetyl.Pro.Leu.Gly.Leu.N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl.Al_a.Arg.NH₂ in the presence or absence of inhibitors. Activity is determined by measuring the fluorescence at λ_{ex} 328nm and λ_{em} 393nm. Percent inhibition is calculated as follows: % Inhibition is equal to the $[\text{Fluorescence}_{\text{plus inhibitor}} - \text{Fluorescence}_{\text{background}}]$ divided by the $[\text{Fluorescence}_{\text{minus inhibitor}} - \text{Fluorescence}_{\text{background}}]$.

A similar protocol can be used for other expressed and purified pro MMPs using substrates and buffers conditions optimal for the particular MMP, for instance as described in C. Graham Knight *et al.*, (1992) FEBS Lett. 296(3):263-266.

Adamalysin family including for example TNF convertase

The ability of the compounds to inhibit proTNF α convertase enzyme may be assessed using a partially purified, isolated enzyme assay, the enzyme being obtained from the membranes of THP-1 as described by K. M. Mohler *et al.*, (1994) Nature 370:218-220.

5 The purified enzyme activity and inhibition thereof is determined by incubating the partially purified enzyme in the presence or absence of test compounds using the substrate 4',5'-Dimethoxy-fluoresceinyl Ser.Pro.Leu.Ala.Gln.Ala.Val.Arg.Ser.Ser.Ser.Arg.Cys(4-(3-succinimid-1-yl)-fluorescein)-NH₂ in assay buffer (50mM Tris HCl, pH 7.4 containing 0.1% (w/v) Triton X-100 and 2mM CaCl₂), at 26°C for 18 hours. The amount of inhibition
10 is determined as for MMP13 except λ_{ex} 490nm and λ_{em} 530nm were used. The substrate was synthesised as follows. The peptidic part of the substrate was assembled on Fmoc-NH-Rink-MBHA-polystyrene resin either manually or on an automated peptide synthesiser by standard methods involving the use of Fmoc-amino acids and O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) as coupling agent with at
15 least a 4- or 5-fold excess of Fmoc-amino acid and HBTU. Ser¹ and Pro² were double-coupled. The following side chain protection strategy was employed; Ser¹(But), Gln⁵(Trityl), Arg^{8,12}(Pmc or Pbf), Ser^{9,10,11}(Trityl), Cys¹³(Trityl). Following assembly, the N-terminal Fmoc-protecting group was removed by treating the Fmoc-peptidyl-resin with 20% piperidine in DMF. The amino-peptidyl-resin so obtained was acylated by treatment
20 for 1.5-2hr at 70°C with 1.5-2 equivalents of 4',5'-dimethoxy-fluorescein-4(5)-carboxylic acid [Khanna & Ullman, (1980) Anal Biochem. 108:156-161) which had been preactivated with diisopropylcarbodiimide and 1-hydroxybenzotriazole in DMF]. The dimethoxyfluoresceinyl-peptide was then simultaneously deprotected and cleaved from the resin by treatment with trifluoroacetic acid containing 5% each of water and triethylsilane.
25 The dimethoxyfluoresceinyl-peptide was isolated by evaporation, trituration with diethyl ether and filtration. The isolated peptide was reacted with 4-(N-maleimido)-fluorescein in DMF containing diisopropylethylamine, the product purified by RP-HPLC and finally isolated by freeze-drying from aqueous acetic acid. The product was characterised by MALDI-TOF MS and amino acid analysis.

Natural Substrates

The activity of the compounds of the invention as inhibitors of aggrecan degradation may be assayed using methods for example based on the disclosures of E. C. Arner *et al.*, (1998) Osteoarthritis and Cartilage 6:214-228; (1999) Journal of Biological Chemistry, 274 (10), 6594-6601 and the antibodies described therein. The potency of compounds to act as inhibitors against collagenases can be determined as described by T. Cawston and A. Barrett (1979) Anal. Biochem. 99:340-345.

Inhibition of metalloproteinase activity in cell/tissue based activity

Test as an agent to inhibit membrane sheddases such as TNF convertase

The ability of the compounds of this invention to inhibit the cellular processing of TNF α production may be assessed in THP-1 cells using an ELISA to detect released TNF essentially as described K. M. Mohler *et al.*, (1994) Nature 370:218-220. In a similar fashion the processing or shedding of other membrane molecules such as those described in N. M. Hooper *et al.*, (1997) Biochem. J. 321:265-279 may be tested using appropriate cell lines and with suitable antibodies to detect the shed protein.

Test as an agent to inhibit cell based invasion

The ability of the compound of this invention to inhibit the migration of cells in an invasion assay may be determined as described in A. Albini *et al.*, (1987) Cancer Research 47:3239-3245.

Test as an agent to inhibit whole blood TNF sheddase activity

The ability of the compounds of this invention to inhibit TNF α production is assessed in a human whole blood assay where LPS is used to stimulate the release of TNF α . Heparinized (10Units/ml) human blood obtained from volunteers is diluted 1:5 with medium (RPMI1640 + bicarbonate, penicillin, streptomycin and glutamine) and incubated (160 μ l) with 20 μ l of test compound (triplicates), in DMSO or appropriate vehicle, for 30 min at 37°C in a humidified (5%CO₂/95%air) incubator, prior to addition of 20 μ l LPS (E. coli. 0111:B4; final concentration 10 μ g/ml). Each assay includes controls of diluted blood incubated with medium alone (6 wells/plate) or a known TNF α inhibitor as standard. The

plates are then incubated for 6 hours at 37°C (humidified incubator), centrifuged (2000rpm for 10 min; 4°C), plasma harvested (50-100µl) and stored in 96 well plates at -70°C before subsequent analysis for TNFα concentration by ELISA.

5 **Test as an agent to inhibit in vitro cartilage degradation**

The ability of the compounds of this invention to inhibit the degradation of the aggrecan or collagen components of cartilage can be assessed essentially as described by K. M. Bottomley *et al.*, (1997) *Biochem J.* 323:483-488.

10 **Pharmacodynamic test**

To evaluate the clearance properties and bioavailability of the compounds of this invention an ex vivo pharmacodynamic test is employed which utilises the synthetic substrate assays above or alternatively HPLC or Mass spectrometric analysis. This is a generic test which can be used to estimate the clearance rate of compounds across a range
15 of species. Animals (e.g. rats, marmosets) are dosed iv or po with a soluble formulation of compound (such as 20% w/v DMSO, 60% w/v PEG400) and at subsequent time points (e.g. 5, 15, 30, 60, 120, 240, 480, 720, 1220 mins) the blood samples are taken from an appropriate vessel into 10U heparin. Plasma fractions are obtained following centrifugation and the plasma proteins precipitated with acetonitrile (80% w/v final concentration). After
20 30 mins at -20°C the plasma proteins are sedimented by centrifugation and the supernatant fraction is evaporated to dryness using a Savant speed vac. The sediment is reconstituted in assay buffer and subsequently analysed for compound content using the synthetic substrate assay. Briefly, a compound concentration-response curve is constructed for the compound undergoing evaluation. Serial dilutions of the reconstituted plasma extracts are assessed for
25 activity and the amount of compound present in the original plasma sample is calculated using the concentration-response curve taking into account the total plasma dilution factor.

In vivo assessment

Test as an anti-TNF agent

30 The ability of the compounds of this invention as *ex vivo* TNFα inhibitors is assessed in the rat. Briefly, groups of male Wistar Alderley Park (AP) rats (180-210g) are dosed

with compound (6 rats) or drug vehicle (10 rats) by the appropriate route e.g. peroral (p.o.), intraperitoneal (i.p.), subcutaneous (s.c.). Ninety minutes later rats are sacrificed using a rising concentration of CO₂ and bled out via the posterior vena cavae into 5 Units of sodium heparin/ml blood. Blood samples are immediately placed on ice and centrifuged at 2000 rpm for 10 min at 4°C and the harvested plasmas frozen at -20°C for subsequent assay of their effect on TNFα production by LPS-stimulated human blood. The rat plasma samples are thawed and 175μl of each sample are added to a set format pattern in a 96 well plate. Fifty μl of heparinized human blood is then added to each well, mixed and the plate is incubated for 30 min at 37°C (humidified incubator). LPS (25μl; final concentration 10μg/ml) is added to the wells and incubation continued for a further 5.5 hours. Control wells are incubated with 25μl of medium alone. Plates are then centrifuged for 10 min at 2000 rpm and 200μl of the supernatants are transferred to a 96 well plate and frozen at -20°C for subsequent analysis of TNF concentration by ELISA.

Data analysis by dedicated software calculates for each compound/dose:

$$\text{Percent inhibition of TNF}\alpha = \frac{\text{Mean TNF}\alpha (\text{Controls}) - \text{Mean TNF}\alpha (\text{Treated}) \times 100}{\text{Mean TNF}\alpha (\text{Controls})}$$

Test as an anti-arthritic agent

Activity of a compound as an anti-arthritic is tested in the collagen-induced arthritis (CIA) as defined by D. E. Trentham *et al.*, (1977) J. Exp. Med. 146:857. In this model acid soluble native type II collagen causes polyarthritis in rats when administered in Freund's incomplete adjuvant. Similar conditions can be used to induce arthritis in mice and primates.


Test as an anti-cancer agent

Activity of a compound as an anti-cancer agent may be assessed essentially as described in I. J. Fidler (1978) Methods in Cancer Research 15:399-439, using for example the B16 cell line (described in B. Hibner *et al.*, Abstract 283 p75 10th NCI-EORTC Symposium, Amsterdam June 16 – 19 1998).

The invention will now be illustrated but not limited by the following Examples:

EXAMPLE 1

Hydroxy[4-pyrimidin-2-yl-1-([4-(4-thien-3-ylphenyl)piperazin-1-yl)sulfonyl}methyl)butyl]formamide



Formic acid (1.44ml) and acetic anhydride (0.4ml) were mixed together at 0°C for 30 minutes, before being added to a solution of 2-(4-(hydroxyamino)-5-{[4-(4-thien-3-ylphenyl)piperazin-1-yl)sulfonyl}pentyl)pyrimidine (105mg) in tetrahydrofuran (10ml) and formic acid (0.5ml) at 0°C. The reaction was allowed to reach room temperature and was stirred overnight, evaporated to dryness and the residue was dissolved in methanol. The solution was stirred overnight and then evaporated to dryness to yield an oil. The oil was triturated with ether to yield a solid, which was collected and dried overnight. Yield 58mg.

NMR (d6-DMSO@373k) δ 9.4, br, 1H; 8.7, d, 2H; 8.1, br, 1H; 7.5, m, 2H; 7.4, m, 1H; 7.25, m, 2H; 7.1, m, 1H; 7.0, m, 2H; 3.6-3.3, m, 8H; 3.2, m, 1H; 2.9, m, 4H; 1.75, br m, 4H.

MS MH⁺ 516

The starting material was prepared as follows :

i) To a solution of 1-(4-bromophenyl)piperazine hydrochloride (5.09 g, 18.3 mmol) and triethylamine (7.67 ml) in dichloromethane (100 ml) was added methanesulfonyl chloride (2.83ml, 36.3 mmol) dropwise. The mixture was stirred for 1 hour at room temperature then dichloromethane (100ml) was added. The organics were washed with water (2x), brine and dried (Na_2SO_4) and evaporated in vacuo to a yellow solid which crystallised from Ethanol and washed with diethyl ether to give 1-(4-bromophenyl)-4-(methanesulfonyl)piperazine (4.74 g, 81% yield) as a white fluffy powder.

^1H NMR (300MHz CDCl_3) δ /ppm: 7.38 (d, 2H), 6.91 (d, 2H), 3.21 (m, 8H), 2.89 (s, 3H)

MS: ES^+ , $(\text{M}+\text{H})^+ = 318, 320$ (Br isotope pattern)

ii) To the 1-(4-bromophenyl)-4-(methanesulfonyl)piperazine (902mg, 2.0mmol) suspended in anhydrous THF (15ml), under Nitrogen, cooled to between -20 and -30°C was added sequentially Lithium bis(trimethylsilyl)amide (1.0M in THF, 4.0ml), Chlorotrimethylsilane (217mg, 2.0mmol, 253 μl) and 4-pyrimidin-2-ylbutanal (300mg, 2.0mmol). The mixture was stirred at -20°C for 1 hour, quenched with saturated ammonium chloride solution and allowed to stand at ambient temperature overnight. The solvents were removed in vacuo and the residue partitioned between dichloromethane (15ml) and water (5ml), the organics separated and chromatogrammed (50g Silica Bond Elute, eluted with 0_100% Ethyl Acetate / Hexane gradient) to give 2-(-5-[4-(4-bromophenyl)piperazin-1-yl]sulfonyl}pent-4-enyl)pyrimidine as a white crystalline material (759mg, 84%Yield)

MS: ES^+ , $(\text{M}+\text{H})^+ = 451, 453$ (Br isotope pattern)

NMR (CDCl_3) δ 8.6, d, 2H; 7.3, m, 2H; 7.15, m, 1H; 6.75, m, 2H; 6.2, m, 2H; 3.35, m, 8H; 3.05, m, 2H; 2.8-2.35, m, 2H; 2.0, m, 2H;

(iii) 2-(-5-[4-(4-bromophenyl)piperazin-1-yl]sulfonyl}pent-4-enyl)pyrimidine (451mg) was dissolved in dimethoxy ethane (20ml) under an argon atmosphere. Thiophene-2-boronic acid (154mg) and tetrakis(triphenylphosphine)palladium (102mg) were added, followed by saturated NaHCO_3 solution (7ml). The reaction mixture was refluxed under argon for 3.5 hours, cooled and partitioned between ethyl acetate and water. The organic

phase was collected, dried over MgSO₄, filtered and evaporated to dryness to yield the crude product 2-(-5-{[4-(4-thien-3-ylphenyl)piperazin-1-yl]sulfonyl}pent-4-enyl)pyrimidine. The crude product was used without further purification, yield 450 mg.

5 NMR (CDCl₃) δ 8.64, d, 1H; 7.7-6.9, m, 9H; 6.1, m, 1H; 3.3, m, 8H; 8.05, m, 2H; 2.75-2.4, m, 2H; 2.0, m, 2H.

MS MH⁺ 455


10 (iv) The crude alkene 2-(-5-{[4-(4-thien-3-ylphenyl)piperazin-1-yl]sulfonyl}pent-4-enyl)pyrimidine (450 mg) was dissolved in tetrahydrofuran (20ml) and hydroxylamine (50% in water) (7ml) was added. The mixture was stirred at ambient temperature overnight. Solvent was removed by evaporation and the residue was partitioned between dichloromethane and water. The organic phase was dried over MgSO₄, filtered and
15 evaporated to dryness. The residue was flash column chromatographed, eluting with 2.5% methanol/ 97.5% ethyl acetate to give 2-(4-(hydroxyamino)-5-{[4-(4-thien-3-ylphenyl)piperazin-1-yl]sulfonyl}pentyl)pyrimidine as a white solid. Yield 200mg.

NMR d₆-DMSO@ 373K δ 8.65, d, 2H; 7.45, m, 2H; 7.3, m, 1H; 7.25, m, 2H; 7.16, m,
20 1H; 6.95, m, 3H; 3.4-3.2, m, 10H; 3.05, m, 1H; 2.9, m, 2H; 1.9, m, 2H; 1.6, m, 2H.


MS MH⁺ 488

EXAMPLE 2

The following analogues were prepared by the method given in Example 1 using the appropriate boronic acid in place of thiophene-2-boronic acid:



R	MH ⁺	NMR d6-DMSO δ
4-Pyridyl	511	9.5,br,1H;8.7,d,2H;8.5,d,2H; 8.15,b,1H;7.7,m,2H;7.55,m,2H 7.3,m,1H;7.1,m,1H;3.4,m,8H; 3.2,dd,1H;2.9,m,3H;1.75,m,4H.
3-Pyridyl	511	9.4,br,1H;8.8,d,1H;8.6,d,1H; 8.5,d,1H;7.9,m,1H;7.55,m,2H; 7.3,m,1H;7.2,m,1H;7.0,m,2H 3.3,m,8H;3.2,m,1H;2.85,m,3H; 1.8,m,4H.
3-Furan	500	9.75,br,1H;8.7,m,2H;8.1,m,2H; 7.7,m,1H;7.4,m,2H;7.2,m,1H; 6.95,m,2H;6.85,d,1H; 3.2,m,10H;2.9,m,2H;1.7,m,4H.
2-Thiophen	516	9.4,br,1H;8.7,d,2H;8.1,br,1H; 7.5,m,4H;7.4,m,1H;7.2,m,1H; 6.9,m,2H;3.4,m,4H;3.25,m,4H; 3.1,m,1H;2.9,m,4H;1.7,m,4.
2-(4-methyl)thiophen	530	9.7,br,1H;8.7,m,2H; 8.15,br,1H;7.5,m,2H;7.3,m,1H; 7.2,m,1H;6.95,m,3H; 3.3,br m,10H;2.9,m,2H; 2.2,s,3H;1.7,m,4H.

EXAMPLE 3**1-[(4-[5-(4-fluorophenyl)pyridin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide**

With stirring, under argon, 2-[5-(4-[5-(4-fluorophenyl)pyridin-2-yl]piperazin-1-yl)sulfonyl)-4-(hydroxyamino)pentyl]pyrimidine (365mg, 0.73mmol) was dissolved in tetrahydrofuran (3.5ml) / formic acid (1.75ml). With ice cooling was added dropwise a preformed mixture of formic acid (880μl) and acetic anhydride (410μl, 4.38mmol). The mixture was allowed to stir at room temperature for 1 hour before the solvents were evaporated and the residue dissolved in dichloromethane and washed with saturated sodium hydrogen carbonate solution. The organic layer was dried (Mg2SO4), evaporated and treated with methanol (10ml) at 50°C for 30 minutes, then evaporated and chromatogrammed by semi-prep HPLC (8μm Hyperprep HS C18 (250mm x 21.2mm), eluent H₂O/MeCN/MeOH/TFA: 67.5/12.5/20/0.5) to give the title compound as a white powder (97mg, 25% yield)

NMR (400Mz, DMSO-d₆, 373K), δ/ppm: 9.40 (1H, br s), 8.68 (2H, m), 8.42 (1H, d), 8.13 (1H, br s), 7.83 (1H, m), 7.62 (2H, m), 7.23 (3H, m), 6.93 (1H, d), 4.80-4.10 (1H, br s), 3.68 (4H, m), 3.46 (1H, dd), 3.30 (4H, m), 3.18 (1H, dd), 2.91 (2H, t), 1.90-1.65 (4H, m)

Mass: ES⁺ (M+H)⁺ 529

The starting material was prepared as follows:

(i) 2-(5-{[4-(5-bromopyridin-2-yl)piperazin-1-yl]sulfonyl}pent-4-enyl)pyrimidine

Prepared as a mixture of E and Z geometrical isomers using the method given in example

1(ii) - using 1-(5-bromo-pyridin-2-yl)-4-(methanesulfonyl)piperazine in place of 1-(4-bromophenyl)-4-(methanesulfonyl)piperazine

NMR (300Mz, DMSO-d₆, 273K), δ /ppm: 8.71 (2H, m), 8.19 (1H, m), 7.71 (1H, m), 7.33 (1H, m), 6.87 (1H, m), 6.65 (*), 6.47 (1H, m), 6.30 (1,d), 3.60 (4H, m), 3.09 (4H, m), 2.88 (2H, dd), 2.57 (1H, dd), 2.29 (1H,t), 1.91 (2H, m)

* minor geometrical isomer

(ii) 2-[(5-({4-[5-(4-fluorophenyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)pent-4-enyl]pyrimidine

Under argon, a flask was charged with 4-fluorophenyl boronic acid (232mg, 1.66mmol), Bis(triphenylphosphine)palladium chloride (15.4mg, 0.022mmol) and 2-(5-{[4-(5-bromopyridin-2-yl)piperazin-1-yl]sulfonyl}pent-4-enyl)pyrimidine(500mg, 1.10mmol). To this were added toluene (10ml) and potassium carbonate (401mg, 2.9mmol) in water (5ml) and the mixture stirred at 75°C, under argon, for 4 days. The mixture was cooled and added to water (50ml), then extracted with dichloromethane (2 x 50ml). The extracts were combined, dried, evaporated and chromatogrammed on silica (50g, EtOAc eluent) to give the title compound as a white powder (406mg, 79%)

Mass: ES⁺ (M+H)⁺ = 468

(iii) 2-[5-({4-[5-(4-fluorophenyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)-4-(hydroxyamino)pentyl]pyrimidine


Under argon, hydroxylamine (50% solution in water, 460 μ l) was added to a stirred solution of 2-[(5-({4-[5-(4-fluorophenyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)pent-4-enyl]pyrimidine (350g, 0.75mmol) in THF (6ml) and the mixture stirred at room temperature overnight. The solvent was evaporated and the residue azeotroped with

toluene (2 x 20ml) and triturated with diethylether to give the title compound as a white powder (375mg, 100%)

Mass: ES⁺ (M+H)⁺ = 501

EXAMPLE 4

1-[(4-[5-(4-chlorophenyl)pyridin-2-yl]piperazin-1-yl)sulfonylmethyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide




By analogy to Example 3 the title compound was prepared.

NMR (400Mz, DMSO-d₆, 373K), δ /ppm: 9.45 (1H, br s), 8.70 (2H, d), 8.46 (1H, d), 8.15 (1H, br s), 8.89 (1H, dd), 7.62 (2H, dd), 7.48 (2H, dd), 7.29 (1H, t), 6.96 (2H, d), 4.80-4.05 (1H, br s), 3.66 (4H, t), 3.45 (1H, dd), 3.31 (4H, t), 2.88 (2H, t), 1.90-1.60 (4H, m)

Mass: ES⁺ (M+H)⁺ = 545, 547 (Cl isotope pattern)

EXAMPLE 5

1-[(4-[5-(3-furyl)pyridin-2-yl]piperazin-1-yl)sulfonylmethyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide




By analogy to Example 3 the title compound was prepared.

NMR (400Mz, DMSO-d₆, 373K), δ /ppm: 9.45 (1H, br s), 8.70 (2H, d), 8.42 (1H, d), 8.14 (1H, br s), 8.01 (1H, s), 7.77 (2H, m), 7.68 (1H, s), 7.29 (1H, t), 6.95 (2H, m) 4.90-3.95 (1H, br s), 3.65 (4H, t), 3.44 (1H, dd), 3.32 (4H, t), 3.18 (1H, dd), 2.89 (2H,t), 1.90-1.60 (4H, m)

Mass: ES+ (M+H)⁺ = 501

EXAMPLE 6

1-([4-(2,3'-bipyridin-6'-yl)piperazin-1-yl]sulfonyl)methyl)-4-pyrimidin-2-ylbutyl(hydroxy)formamide



Under Argon, a preformed mixture of formic acid (1.0ml) and acetic anhydride (378 μ l, 408mg, 4.0mmol) was added dropwise to a solution of 6'-4-{[2-(hydroxyamino)-5-pyrimidin-2-ylpentyl]sulfonyl}piperazin-1-yl)-2,3'-bipyridine (103mg, 0.21mmol) in THF (5ml) / formic acid (2.5ml), cooled to 0°C. The mixture was allowed to warm to room temperature and stirred for 1 hour. The solvents were then evaporated and the residue dissolved in dichloromethane (20ml) and stirred with saturated sodium bicarbonate solution (10ml) for 1hour. The organics were separated and purified on silica (20g, EtOAc eluent) to give the title compound as a white powder (60mg, 56% yield)

NMR (300Mz, DMSO-d₆, 373K), δ /ppm: 9.45 (1H, br s), 8.85 (1H, s), 8.70 (2H, d), 8.63 (1H, d), 8.25-7.98 (2H, m), 7.82 (2H, m), 7.28 (2H, m), 6.98 (1H, d), 4.80-4.00 (1H, br s), 3.72 (4H, t), 3.42 (1H, dd), 3.33 (4H, t), 3.19 (1H, dd), 2.89 (2H, t), 1.90-1.70 (4H, m)
Mass: ES⁺ (M+H)⁺ = 512

The starting material was prepared as follows:

6'-(4-{[2-(hydroxyamino)-5-pyrimidin-2-ylpentyl]sulfonyl}piperazin-1-yl)-2,3'-bipyridine

Under argon, hydroxylamine (50% solution in water, 0.5ml) was added to a solution of 6'-(4-{[5-pyrimidin-2-ylpent-1-enyl]sulfonyl}piperazin-1-yl)-2,3'-bipyridine (96mg, 0.21mmol) in dry THF (4.0ml) and the mixture stirred at room temperature overnight. Evaporation of the solvents yielded the title compound as a yellow powder (103mg, 100% yield)

Mass: ES⁺ (M+H)⁺ = 484


6'-(4-{[5-pyrimidin-2-ylpent-1-enyl]sulfonyl}piperazin-1-yl)-2,3'-bipyridine

Under argon, 2-(5-{[4-(5-bromopyridin-2-yl)piperazin-1-yl]sulfonyl}pent-4-enyl)pyrimidine (226mg, 0.5mmol) and tetrakis(triphenylphosphine)palladium (29mg, 0.025mmol) were dissolved in dry toluene (10ml) and to the stirred solution was added 2-(tri-n-butylstannyl)pyridine (276mg, 0.75mmol) in dry toluene (1ml). The mixture was heated to 95°C overnight, cooled and then was added potassium fluoride (2M, 2.0ml) and the mixture stirred at room temperature for 5 hours. The mixture was extracted with dichloromethane (10ml) and the organic layer passed through a PTFE robot filter, evaporated and chromatogrammed on silica gel (2.5% Methanol / Dichloromethane eluent) to give a pale yellow powder (100mg, 44%)

Mass: ES⁺ (M+H)⁺ = 451

EXAMPLE 7

hydroxy[4-pyrimidin-2-yl-1-({[4-(5-thien-2-ylpyridin-2-yl)piperazin-1-yl]sulfonyl}methyl)butyl]formamide




By analogy with Example 5, the title compound was obtained as a white powder (80mg, 35%)

NMR (300Mz, DMSO-d₆, 373K), δ /ppm: 9.40 (1H, br s), 8.69 (2H, d), 8.44 (1H, d), 8.25-7.98 (1H, m), 7.80 (1H, dd), 7.43 (1H, dd), 7.33 (1H, dd), 7.29 (1H, t), 7.10 (1H, t), 6.90 (1H, d), 4.80-4.00 (1H, br s), 3.67 (4H, t), 3.44 (1H, dd), 3.32 (4H, t), 3.18 (1H, dd), 2.89 (2H, t), 1.87-1.63 (4H, m)

EXAMPLE 8

1-[(4-[5-(2-furyl)pyridin-2-yl]piperazin-1-yl)sulfonyl]methyl-4-pyrimidin-2-ylbutyl(hydroxy)formamide




By analogy with example 5, the title compound was obtained as a white powder (56mg, 27%)

Mass: ES+(M+H)+ = 501

NMR (500Mz, DMSO-d₆, 373K), δ /ppm: 9.39 (1H, br s), 8.67 (2H, d), 8.47 (1H, d), 8.10 (1H, br s), 7.80 (1H, dd), 7.60 (1H, d), 7.24 (1H, t), 6.89 (1H, d), 6.68 (1H, d), 6.51 (1H, dd), 4.40 (1H, br s), 3.65 (4H, t), 3.43 (1H, dd), 3.29 (4H, t), 3.17 (1H, dd), 2.88 (2H, t), 1.85-1.63 (4H, m)

EXAMPLE 9

1-[(4-[5-(4-fluorophenyl)pyrazin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide



Formic acid (1.40ml) and acetic anhydride (0.38ml) were mixed together at 0°C for 30 minutes, before being added to a solution of 2-[5-({4-[5-(4-fluorophenyl)pyrazin-2-yl]piperazin-1-yl}sulphonyl)-4-(hydroxyamino)pentyl]pyrimidine (290mg) in tetrahydrofuran (10ml) and formic acid (1.0ml) at 0°C. The reaction was allowed to reach room temperature and was stirred overnight, neutralised with saturated sodium bicarbonate solution and extracted with dichloromethane. The organic phase was dried over magnesium sulphate, filtered, evaporated to dryness and the residue was dissolved in methanol. The solution was stirred overnight and then evaporated to dryness to yield an oil. The oil was triturated with ether to yield, 1-[(4-[5-(4-fluorophenyl)pyrazin-1-yl]piperazin-1-yl)sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide. Yield 210mg.

NMR (DPX400 CD₃Cl) δ 9.7, br d, 1H; 8.7, m, 3H; 8.4, d, 1H; 8.0, m, 2H; 7.3, m, 3H; 4.7-4.2, d, 1H; 3.8, m, 4H; 3.3, br m, 6H; 2.9, m, 2H; 1.7, br m, 4H.

MS MH⁺ 530.03

The starting material was prepared as follows :

i) To a solution of 2-chloro-5-(4-fluorophenyl)pyrazine (3.45g) {CA Reg No 115104-61-5} in dimethylacetamide (25ml) was added anhydrous piperazine (4.4g). The solution was stirred at 120°C overnight. Cooled and evaporated in vacuo to an oily solid. Stirred in ethyl acetate for 1 hour. The insoluble material was removed by filtration. The organic filtrate was dried over magnesium sulphate, filtered and evaporated to yield 2-(4-fluorophenyl)-5-piperazin-1-ylpyrazine. Yield 4.1g

NMR (DPX400 CD₃Cl) δ 8.5, d, 1H; 8.2, d, 1H; 7.8, m, 2H; 7.1, d, 2H; 3.65, m, 4H; 3.1, m, 4H

MS MH⁺ 259.06

ii) To a solution of 2-(4-fluorophenyl)-5-piperazin-1-ylpyrazine (2.58g, 0.01M) and triethylamine (4.2 ml) in dichloromethane (100 ml) at 0°C was added methanesulphonyl chloride (0.96ml, 0.011M) dropwise. The mixture was stirred overnight at room temperature, then dichloromethane (100ml) was added. The organics were washed with water, dried (Magnesium sulphate) and evaporated in vacuo to a yellow solid which crystallised from ethanol to give 2-(4-fluorophenyl)-5-[4-(methylsulphonyl)piperazin-1-yl]pyrazine. Yield 2.7g.

NMR (400MHz CD₃Cl) δ 8.5, d, 1H; 8.2, d, 1H; 7.9, m, 2H; 7.15, m, 2H; 3.8, m, 4H; 3.4, m, 4H; 2.85, s, 3H.

MS MH⁺ 337.01

iii) To the 2-(4-fluorophenyl)-5-[4-(methylsulphonyl)piperazin-1-yl]pyrazine (840mg, 0.0025M) dissolved in anhydrous THF (200ml), under argon, and cooled to -10°C was added Lithium bis(trimethylsilyl) amide (1.0M in THF 5.5 ml 0.0055M). Diethyl

chorophosphate (0.37ml, 0.0025M) and a solution of 4-pyrimidin-2-ylbutanal (375mg, 0.0025M) in dry THF(5ml) were added sequentially. The mixture was stirred at -10°C for 1 hour, quenched with saturated ammonium chloride solution and extracted with ethyl acetate. The organic phase was dried over magnesium sulphate, filtered and evaporated to an oily solid. Chromatographed on Merck 9385 silica, eluting with ethyl acetate to yield 2-[4-5-({4-[5-(4-fluorophenyl)pyrazin-1-yl}pent-4-enyl]pyrimidine as a solid. Yield 325mg.

NMR 400MHz CD₃Cl δ 8.7,m,2H; 8.5, s,1H; 7.9,m,2H; 7.15, m,2H; 6.85,m,1H; 6.4,m, 6.1,dd,2H; 3.8,m,4H; 3.3,m,H;3.1,m,2H; 2.75-2.3 dm,2H;2.5,m,2H.

MS MH⁺ 469.03


iv) The alkene 2-[4-5-({4-[5-(4-fluorophenyl)pyrazin-1-yl}pent-4-enyl]pyrimidine (310 mg) was dissolved in tetrahydrofuran (10ml) and hydroxylamine (50% in water) (2ml) was added. The mixture was stirred at ambient temperature overnight. The reaction mixture was partitioned between saturated ammonium chloride solution and dichloromethane. The organic phase was dried over magnesium sulphate, filtered and evaporated to give 2-[5-({4-[5-(4-fluorophenyl)pyrazin-1-yl}sulphonyl)-4-(hydroxyamino]pyrimidine as a white solid. Yield 297mg

NMR 400MHz CD₃Cl δ 8.65, d, 2H; 8.5, d, 1H; 8.15, d, H; 7.8,,m, 2H; 7.2, m, 2H; 3.73, m, 4H; 3.4, m, 5H; 3.2-2.9, m, 2H; 1.9, m, 2H; 1.65,m,2H..

MS MH⁺ 502.03

EXAMPLE 10

hydroxy[1-({[4-(5-phenylpyrazin-2-yl)piperazin-1-yl]sulfonyl}methyl)-4-pyrimidin-2-ylbutyl]formamide




By analogy with example 9, the above compound was synthesised starting from the analogous chloropyrazine CA Reg No 25844-73-9

MS MH⁺ 512.05

EXAMPLE 11

1-[(4-[5-(3-furyl)pyridin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide



To a ice-cooled solution of 2-[5-({4-[5-(3-furyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)-4-(hydroxyamino)pentyl]pyrimidine (426mg, 0.90mmol) in a mixed solvent system of THF/formic acid (6ml/2ml) was added a preformed mixture of formic acid (2.0ml) and acetic anhydride (1ml). The mixture was then stirred at room temperature for 1 hour. The solvents were evaporated and the residue partitioned between dichloromethane (15ml) and

saturated Sodium Bicarbonate solution (10ml) and stirred at ambient temperature overnight. The organic layer was then separated using a PTFE (0.45 micron) robot filter, evaporated and the residue was purified by flash chromatography (silica gel, 10g, 0 - 10% EtOH / EtOAc) to give the title compound as a white powder (266mg, 59% yield)

NMR (400Mz, DMSO-D6, 373K), δ /ppm: 9.39 (1H, br s), 8.68 (2H, d), 8.40 (1H, d), 8.13 (1H, br s), 7.99 (1H, t), 7.76 (1H, dd), 7.67 (1H, t), 7.27 (1H, t), 6.85 (2H, dd), 4.40 (1H, br s), 3.64 (4H, t), 3.44 (1H, dd), 3.32 (4H, t), 3.17 (1H, t), 2.91 (2H, t), 1.77 (4H, m)

Mass: ES⁺ (M+H)⁺ = 501

Chiral chromatography: The enantiomers of 1-[(4-[5-(3-furyl)pyridin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide were resolved on Daicel Chiralpak AD 2cm x 25cm column with eluent of 10%MeOH / MeCN

The starting material was prepared as follows:

i) 2-[(4E,Z)-5-({4-[5-(3-furyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)pent-4-enyl]pyrimidine

To a stirred solution of 2-((4E,Z)-5-{[4-(5-bromopyridin-2-yl)piperazin-1-yl]sulfonyl}pent-4-enyl)pyrimidine (440mg, 0.97mmol) in DME (20ml), under Argon at RT, was added 3-furylboronic acid (134mg, 1.2mmol), tetrakis(triphenylphosphine)palladium (102mg, 10 mol %) and saturated sodium bicarbonate solution (7ml). The mixture was heated to reflux for 3 hours. After cooling to room temperature, the mixture was partitioned between dichloromethane (20ml) and water (10ml). The organic phase was separated using a PTFE (0.45 micron) robot filter and purified by flash chromatography (silica gel, 20g, 50-100% EtOAc / iso-hexane) to give the title compound as a pale yellow solid (407mg, 95%).

NMR (400Mz, DMSO-D6, 373K), δ /ppm: 8.67 (2H,d), 8.46 (1H, d), 7.88 (1H, dd),

7.64 (1H, m), 7.47 (2H, d), 7.31 (1H, t), 6.96 (1H, d), 6.69 (1H, m), 6.50 (1H, d), 3.67 (4H, t), 3.11 (4H, t), 2.87 (2H, t), 2.30 (2H, m), 1.93 (2H, m)

Mass: ES+ (M+H)+=440


ii) 2-[5-({4-[5-(3-furyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)-4-(hydroxyamino)pentyl]pyrimidine

A stirred solution of 2-[(4*E,Z*)-5-({4-[5-(3-furyl)pyridin-2-yl]piperazin-1-yl}sulfonyl)pent-4-enyl]pyrimidine (395mg, 0.90mmol) in THF (10ml), under Argon, was treated at room temperature with hydroxylamine (50% solution in H₂O, 1.0ml) for 2.5 hours. The solvents were evaporated to give the title compound, 426mg, 99%

Mass: ES+ (M+H)+ = 473

EXAMPLE 12

The following compounds were prepared using the method given in Example 11.



Ar	R1	M+H
3-Pyridyl	2-PyrimidinylCH ₂ CH ₂ CH ₂	512.5
4-Pyridyl	2-PyrimidinylCH ₂ CH ₂ CH ₂	512.5
3,4-difluorophenyl	2-PyrimidinylCH ₂ CH ₂ CH ₂	547.5
Thien-3-yl	2-PyrimidinylCH ₂ CH ₂ CH ₂	517.5

Ar	R1	M+H
4-fluorophenyl	2-PyrimidinylCH ₂ CH ₂ CH ₂	529.4 <i>i.</i>
4-fluorophenyl	5-F-2-PyrimidinylCH ₂ CH ₂	533.3
Pyrimidin-5-yl	2-PyrimidinylCH ₂ CH ₂ CH ₂	513.1
2,4-difluorophenyl	2-PyrimidinylCH ₂ CH ₂ CH ₂	547.0
2-chlorophenyl	2-PyrimidinylCH ₂ CH ₂ CH ₂	545.0 & 547.0 <i>ii.</i>
2-fluorophenyl	2-PyrimidinylCH ₂ CH ₂ CH ₂	529.0
2,4-di-MeO-pyrimidin-5-yl	2-PyrimidinylCH ₂ CH ₂ CH ₂	573.1


NOTES

i. Resolved enantiomers using Daicel Chiralpak AD 2cm x 25cm 10%MeOH / MeCN eluent

ii. Chlorine isotope pattern

EXAMPLE 13

1-[(4-[5-(4-fluorophenyl)pyrimidin-2-yl]piperazin-1-yl)sulfonyl)methyl]-3-pyrimidin-2-ylpropyl(hydroxy)formamide



Formic acid (2.63 mL, 70 mmol) and acetic anhydride (0.7 mL, 7 mmol) were mixed together at 0°C for 30 minutes, before being added to a solution of 5-(4-fluorophenyl)-2-

(4-{[2-(hydroxyamino)-4-pyrimidin-2-ylbutyl]sulfonyl}piperazin-1-yl)pyrimidine (690 mg, 1.4 mmol) in tetrahydrofuran (10 mL) and formic acid (2.63 mL) at 0°C. The reaction was allowed to reach room temperature and was stirred for 45 minutes. The reaction was then evaporated *in vacuo*, and azeotroped with toluene (2 x 5 mL). The residue was dissolved in MeOH and heated to 45°C for one hour. The solution was then evaporated *in vacuo*, and the residue triturated with Et₂O to give a white solid which was collected by filtration, washed with Et₂O and dried *in vacuo* to give 1-[(4-[5-(4-fluorophenyl)pyrimidin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide as a white solid (417 mg, 57%).

¹H NMR (d6-DMSO@373k) δ 9.45 (br, s, 1 H), 8.68 (m, 4 H), 8.09 (br, s, 1 H), 7.67 (m, 2 H), 7.28 (m, 3H), 4.41 (br, s, 1 H), 3.91 (m, 4 H), 3.49 (dd, 1 H), 3.33 (m, 4 H), 3.29 (dd, 1 H), 2.87 (m, 2 H), 2.21 (m, 2H).

MS (ESI): 516.43 (MH⁺)

The starting material was prepared as follows :

To a stirred solution of *tert*-butyl 4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate (15.5 g, 45.5 mmol, CAS number 374930-88-8) and 4-fluorophenyl-boronic acid (7.63g, 54.5 mmol) in a mixed solvent system of DME:saturated aqueous sodium bicarbonate solution (200 mL:160 mL) at RT was added Pd(PPh₃)₄ (2.6g, 2.25 mmol). The reaction was then stirred for 3 hours at 90°C, before being cooled to RT. The reaction was then quenched with water (200 mL) and the layers were separated. The aqueous phase was extracted with EtOAc (3 x 200 mL) and the combined organic extracts were dried (MgSO₄), filtered and evaporated *in vacuo*. The residue was then purified by flash chromatography (silica gel, 50% EtOAc in hexanes) to give *tert*-butyl 4-[5-(4-fluorophenyl)pyrimidin-2-yl]piperazine-1-carboxylate as a silvery solid (16.6g, 45 mmol, 98%).

¹H NMR (CDCl₃) δ : 8.50 (s, 2 H), 7.43 (m, 2 H), 7.12 (m, 2 H), 3.86 (m, 4 H), 3.52 (m, 4 H), 1.52 (s, 9 H).

MS (ESI): 303.30 (MH⁺ - *t*-Bu)

To a stirred solution of *tert*-butyl 4-[5-(4-fluorophenyl)pyrimidin-2-yl]piperazine-1-carboxylate (16.5 g, 46.1 mmol) in CH₂Cl₂ (50 mL) at RT was added trifluoroacetic acid (40 mL). The mixture was then stirred vigorously at RT for 1 hour. Volatiles were removed *in vacuo*, and the residue was azeotroped with toluene (2 x 50 mL).

5 The crude residue was then dissolved in CH₂Cl₂ (150 mL) and cooled to 0°C. Triethylamine (19.2 mL, 0.13 mol) was then added, followed by dropwise addition of methanesulfonyl chloride (3.9 mL, 50 ml). The reaction was then allowed to stir at RT for one hour, before being quenched by the addition of water (100 mL). The layers were separated, and the aqueous phase extracted with CH₂Cl₂ (2 x 100 mL). The combined
10 organic extracts were dried (MgSO₄), filtered and evaporated *in vacuo* to give 5-(4-fluorophenyl)-2-[4-(methanesulfonyl)piperazin-1-yl]pyrimidine as a colourless solid (12.84 g, 83%).

¹H NMR (CDCl₃) δ : 8.52 (s, 2 H), 7.44 (m, 2 H), 7.16 (m, 2 H), 4.07 (m, 4 H), 3.34 (m, 4
15 H), 2.82 (s, 3 H).

MS (ESI): 337.02 (MH⁺)

To a stirred suspension of 5-(4-fluorophenyl)-2-[4-(methanesulfonyl)piperazin-1-yl]pyrimidine (504 mg, 1.5 mmol) in THF (15 mL) at -78°C, was added dropwise a
20 solution of LiHMDS in THF (3.1 mL, 1.0M solution, 3.1 mmol). The resulting suspension was stirred at -78°C for 30 minutes before being treated with diethyl chlorophosphate (0.23 mL, 1.6 mmol). The solution was then maintained at -78°C for 30 minutes before being warmed slowly to -20°C. The reaction was then treated with a solution of 4-pyrimidin-2-ylbutanal (220 mg, 1.6 mmol) in THF (2 mL). The solution was then maintained at -20 °C
25 for one hour before being quenched with saturated aqueous ammonium chloride solution (5 mL). The layers were separated and the aqueous phase extracted with ethyl acetate (3 x 5 mL). The combined organic extracts were then dried, (MgSO₄), filtered and concentrated *in vacuo* to give 5-(4-fluorophenyl)-2-(4-{[(1*E*/*Z*)-4-pyrimidin-2-ylbut-1-enyl]sulfonyl}piperazin-1-yl)pyrimidine as a brown solid which was used crude in the next
30 step.

MS (ESI): 455.40 (MH⁺)


To a stirred solution of 5-(4-fluorophenyl)-2-(4-{{(1*E/Z*)-4-pyrimidin-2-ylbut-1-enyl}sulfonyl}piperazin-1-yl)pyrimidine (crude from previous step) in THF (10 mL) at RT was added 50% aqueous hydroxylamine (1.5 mL) and the mixture stirred rapidly for 2 hours. The reaction was quenched by the addition of saturated ammonium chloride solution (5 mL) and the layers were then separated. The aqueous phase was extracted with EtOAc (3 x 5 mL) and the combined organic extracts were then dried (MgSO₄), filtered and evaporated *in vacuo*. The white solid obtained was then purified by flash chromatography (silica gel, 5% MeOH in CH₂Cl₂), to give 5-(4-fluorophenyl)-2-(4-{{2-(hydroxyamino)-4-pyrimidin-2-ylbutyl}sulfonyl}piperazin-1-yl)pyrimidine as a white solid (698 mg, 1.48 mmol, 95% over two steps).

¹H NMR (d6-DMSO) δ : 8.72 (m, 4H), 7.67 (m, 2H), 7.29 (m, 3H), 5.68 (br s, 1H), 4.01 (m, 4 H), 3.89 (m, 4H), 3.40 (dd, 1 H), 3.31 (m, 5 H), 3.11 (m, 2 H), 2.11 (m, 2 H).

MS (ESI): 488.42 (MH⁺).

EXAMPLE 14

(1*S*)-1-[(4-[5-(4-fluorophenyl)pyrimidin-2-yl]piperazin-1-yl)sulfonyl]methyl-3-pyrimidin-2-ylpropyl(hydroxy)formamide




The racemic mixture, prepared as in example 13, was separated by chiral HPLC (on a Chiralcel OJ column, 10 μ m, 2cm x 25cm, flow rate 9ml / min eluent = EtOH) to give (1*S*)-1-[(4-[5-(4-fluorophenyl)pyrimidin-2-yl]piperazin-1-yl)sulfonylmethyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide as a white solid

^1H NMR (d₆-DMSO@373k) δ 9.45 (br, s, 1 H), 8.68 (m, 4 H), 8.09 (br, s, 1 H), 7.67 (m, 2 H), 7.28 (m, 3H), 4.41 (br, s, 1 H), 3.91 (m, 4 H), 3.49 (dd, 1 H), 3.33 (m, 4 H), 3.29 (dd, 1 H), 2.87 (m, 2 H), 2.21 (m, 2H).

MS (ESI): 516.43 (MH⁺)

EXAMPLE 15


The following compounds were also prepared using the method given in example 13.



Ar	R1	M+H
4-F-Ph	5-Cl-2-PyrimidinylCH ₂ CH ₂	550.38

EXAMPLE 16

(1*S*)-1-[(4-[5-(4-fluorophenyl)pyrimidin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide



Formic acid (0.37mL, 10 mmol) and acetic anhydride (0.2mL, 2 mmol) were mixed together at 0°C for 30 minutes, before being added to a solution of 5-(4-fluorophenyl)-2-
 (4-{[2-(hydroxyamino)-5-pyrimidin-2-ylpentyl]sulfonyl}piperazin-1-yl)pyrimidine (240
 mg, 0.48 mmol) in tetrahydrofuran (3 mL) and formic acid (0.37mL) at 0°C. The reaction
 was allowed to reach room temperature and was stirred for 45 minutes. The reaction was
 then evaporated *in vacuo*, and azeotroped with toluene (2 x 5 mL). The residue was then
 dissolved in MeOH and heated to 45°C for one hour. The solution was then evaporated *in*
vacuo, and the residue triturated with Et₂O to give a white solid which was collected by
 filtration, washed with Et₂O and dried in *vacuo* (182 mg, 70%). The racemic mixture was
 then separated by chiral HPLC (on a Merck Chiralpak AS-V column, 20 μm, 5cm x 25cm,
 flow rate 35ml / min eluent = 90%EtOH / 10%MeCN/MeOH) to give (1*S*)-1-[(4-[5-(4-
 fluorophenyl)pyrimidin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-
 ylbutyl(hydroxy)formamide as a white solid.

¹H NMR (d₆-DMSO@373k) δ 9.4 (br, s, 1 H), 8.62 (m, 4 H), 8.11 (br, s, 1 H), 7.66 (m,
 2 H), 7.21 (m, 3 H), 4.55 (br, s, 1 H), 3.88 (m, 4 H), 3.45 (dd, 1 H), 3.30 (m, 4 H), 3.16 (m,
 1 H), 2.89 (m, 2 H), 1.68 (m, 4H).

MS (ESI): 530.28 (MH⁺)

The starting material was prepared as follows :

To a stirred solution of 5-bromo-2-piperazin-1-ylpyrimidine (22.38 g, 92 mmol, CAS number 99931-82-5) and triethylamine (38.5 mL, 276 mmol) in dichloromethane (400 mL) at 0°C was added methanesulfonyl chloride (10.7 mL, 138 mmol) dropwise over 10 minutes. The reaction was then stirred for 30 minutes at 0°C, before being allowed to warm to RT and stirred for an additional 30 minutes. The reaction was then quenched with water (200 mL) and the layers were separated. The organic phase was washed with water (200 mL) and the organics were dried (MgSO₄), filtered and evaporated *in vacuo*. The residue was then triturated with ethyl acetate and the solid residue filtered and dried *in vacuo* to give 5-bromo-2-[4-(methanesulfonyl)piperazin-1-yl]pyrimidine as an off white solid (22.4g, 69.6 mmol, 76%).

¹H NMR (CDCl₃) δ : 8.30 (s, 2 H), 3.96 (m, 4 H), 3.28, (m, 4 H), 7.67 (dd, 1 H), 2.81 (s, 3 H).

MS (ESI): 321.18 (MH⁺)

To a stirred suspension of 5-bromo-2-[4-(methanesulfonyl)piperazin-1-yl]pyrimidine (21.36g, 66.5 mmol) in THF (700 mL) at -78°C, was added dropwise a solution of LiHMDS in THF (146 mL, 1.0M solution, 0.146 mol). The resulting suspension was stirred at -78°C for 30 minutes before being treated with diethyl chlorophosphate (10.6 mL, 73.2 mmol). The solution was then maintained at -78°C for 30 minutes before being warmed slowly to -20°C. The reaction was then treated with a solution of 4-pyrimidin-2-ylbutanal (11 g, 73.2 mmol) in THF (50 mL). The solution was then maintained at -20 °C for one hour before being quenched with saturated aqueous ammonium chloride solution (500 mL). The layers were separated and the aqueous phase extracted with ethyl acetate (3 x 300 mL). The combined organic extracts were then dried, (MgSO₄), filtered and concentrated *in vacuo* to give a brown solid which was purified by flash chromatography (silica gel, 25% to 50% to 100% EtOAc in hexanes) to give 5-bromo-2-(4-[(1*E*/*Z*)-5-pyrimidin-2-ylpent-1-enyl]sulfonyl)piperazin-1-ylpyrimidine as a yellow solid (13g, 43%, *E*:*Z* 1.89:1).

¹H NMR (CDCl₃) δ : 8.68 (m, 2 H), 8.27 (m, 2 H), 7.13, (m, 1 H), 6.82 (ddd, 1 H), 6.35 (ddd)*, 6.11 (ddd, 1H), 5.95 (ddd)*, 3.90 (m, 4H), 3.17 (m, 4H), 3.09 (m, 2H), 2.72 (m)*, 2.34 (m, 2H), 2.11 (m, 2H)

* minor geometrical isomer.

MS (ESI): 454.95 (MH⁺ Br isotope pattern).

A stirred solution of 5-bromo-2-(4-{{(1E/Z)-5-pyrimidin-2-ylpent-1-enyl}sulfonyl}piperazin-1-yl)pyrimidine, (453 mg, 1 mmol), Pd(PPh₃)₄ (115 mg, 0.1 mmol) and 4-fluorophenyl boronic acid (166 mg, 1.2 mmol) in a mixed solvent system of DME/saturated aqueous sodium hydrogencarbonate (10 mL:7mL) was heated to 95°C for 3 hours. The mixture was then cooled to room temperature and partitioned between water and EtOAc (5mL:5 mL). The layers were separated, and the aqueous phase extracted with EtOAc (3 x 5 mL). The combined organic extracts were then dried ((MgSO₄), filtered and evaporated *in vacuo*. The solid residue was used crude in the next step.

MS (ESI): 469.00 (MH⁺)


To a stirred solution of 5-(4-fluorophenyl)-2-(4-{{(1E/Z)-5-pyrimidin-2-ylpent-1-enyl}sulfonyl}piperazin-1-yl)pyrimidine (crude from previous step) in THF (10 mL) at RT was added 50% aqueous hydroxylamine (2 mL) and the mixture stirred rapidly for 2 hours. The reaction was quenched by the addition of saturated ammonium chloride solution (5 mL) and the layers were then separated. The aqueous phase was extracted with EtOAc (3 x 5 mL) and the combined organic extracts were then dried (MgSO₄), filtered and evaporated *in vacuo*. The white solid obtained was then purified by flash chromatography (silica gel, 50% to 100% EtOAc in hexanes), to give 5-(4-fluorophenyl)-2-(4-{{[2-(hydroxyamino)-5-pyrimidin-2-ylpentyl}sulfonyl}piperazin-1-yl)pyrimidine as a white solid (245 mg, 0.488 mmol, 49% over two steps).

^1H NMR (CDCl_3) δ : 8.66 (m, 2H), 8.50 (s, 2H), 7.42 (m, 2H), 7.11 (m, 3H), 5.44 (br s, 1H), 4.01 (m, 4 H), 3.44 (m, 5H), 3.21 (m, 1H), 2.94 (m, 1H), 2.82 (dd, 1H), 2.07 (m, 1H), 1.94 (m, 1H), 1.77 (m, 1H), 1.60 (m, 1H).

MS (ESI): 502.02 (MH^+)

EXAMPLE 17

1-[(4-[5-(2-chloro-4-fluorophenyl)pyrimid-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide



With stirring, under argon, 2-[5-({4-[5-(2-chloro-4-fluorophenyl)pyrimid-2-yl]piperazin-1-yl}sulfonyl)-4-(hydroxyamino)pentyl]pyrimidine (260mg, 0.485mmol) was dissolved in dichloromethane (2.5ml) / formic acid (1ml). With ice cooling was added dropwise a mixture of formic acid (1ml) and acetic anhydride (200 μ l) preformed at 8°C. The mixture was allowed to stir at room temperature for 20 minutes before the solvents were evaporated and azeotroped with toluene. The residue was dissolved in dichloromethane (5ml) and treated with methanol (5ml) at room temperature for 18 hours. The solution was evaporated, diluted with dichloromethane and azeotroped several times with diethyl ether to give the title compound as a white powder (248mg, 91% yield)

NMR (300MHz, DMSO-d_6 , 373K), δ /ppm: 8.65 (2H, d), 8.45 (2H, s), 7.5 (2H, m), 7.3 (2H, m), 3.9 (4H, b s), 3.45 (1H, m), 3.30 (4H, b s), 3.15 (1H, dd), 2.9 (2H, b), 1.75 (4H, b)

Mass: ES^+ ($\text{M}+\text{H}$) $^+$ 564, 566 (Cl isotope pattern)

The starting material was prepared as follows:

(i) 2-[(5-({4-[5-(2-chloro-4-fluorophenyl)pyrimid-2-yl]piperazin-1-yl}sulfonyl)pent-4-enyl]pyrimidine

To stirred 2-(5-{[4-(5-bromopyrimid-2-yl)piperazin-1-yl]sulfonyl}pent-4-enyl)pyrimidine (453mg, 1mmol) were added in three aliquots at reaction times of 0, 1 and 5 hrs, Tetrakis(triphenylphosphine)palladium (3 x 46mg, total 120 μ mol) and 2-Chloro-4-fluorophenyl zinc iodide (2 x 1.1ml & 1.5ml, 0.5M in THF, 1.85mmol). After the initial additions, the reaction was heated at 50°C. The mixture was quenched with water (2ml), sodium hydrogen carbonate (sat., 2ml) added and diluted with ethyl acetate. The suspension was filtered and washed well with ethyl acetate. The filtrate was washed with water and brine, back-extracting with ethyl acetate. Dried (MgSO₄) and filtered through silica (2g) washing well with ethyl acetate to give the title compound a mixture of E/Z geometrical isomers as a brown oil (558mg, 93% @ 84wt%)

NMR (300MHz, CDCl₃), δ /ppm: 8.65 (2H, t), 8.4 (2H, s), 7.3 (obscured by PPh₃O), 7.15 (1H, t), 7.05 (2H, m), 6.85, (0.4H, dt), 6.5, (0.6H, dt), 6.15, (0.4H, d), 6.05 (0.6H, d), 4.0 (4H, t), 3.25 (4H, t), 3.0 (2H, q), 2.75 (1.2H, q), 2.35 (0.8H, q), 2.05 (2H, obs)

Mass: ES⁺ (M+H)⁺ = 503, 505 (Cl isotope pattern)

(ii) 2-[5-({4-[5-(2-chloro-4-fluorophenyl)pyrimid-2-yl]piperazin-1-yl}sulfonyl)-4-(hydroxyamino)pentyl]pyrimidine

Under argon, hydroxylamine (50% solution in water, 567 μ l) was added to a stirred solution of 2-[(5-({4-[5-(2-chloro-4-fluorophenyl)pyrimid-2-yl]piperazin-1-yl}sulfonyl)pent-4-enyl]pyrimidine (554mg, 0.925mmol) in tetrahydrofuran (4.5ml) and the mixture stirred at room temperature overnight. The solution was partitioned between ethyl acetate (2x) and brine. The organic phases were dried (MgSO₄) and evaporated, triturated with diethyl ether and decanted. The solid white residue was redissolved in dichloromethane,


evaporated to a low volume and triturated with diethyl ether to give the title compound as a white powder (264mg, 53%)

NMR (300MHz, CDCl₃), δ /ppm: 8.65 (2H, d), 8.4 (2H, s), 7.25 (2H & CHCl₃), 7.15 (1H, t), 7.1 (1H, td), 5.5 (1H, b s), 4.0 (4H, t), 3.5 (1H), 3.45 (1H, d), 3.35 (4H, t), 3.2 (1H, p), 3.05 (1H, p), 2.85 (1H, p), 2.05 (1H, m), 1.95 (1H, m), 1.7 (1H, m), 1.6 (1H, m)

Mass: ES⁺ (M+H)⁺ = 536, 538 (Cl isotope pattern)









EXAMPLE 18











The following analogues were prepared by an analogous manner to that given in Example 16, using the appropriate boronic acid and aldehyde in place of 4-fluorophenyl boronic acid and 4-pyrimidin-2-ylbutanal:




R	MH ⁺
2-Chlorophenyl	546/548
2-Methoxyphenyl	542
4-Ethoxyphenyl	584
4-(Methylthio)phenyl	558
2-(Trifluoromethyl)Phenyl	580
2,4-Difluorophenyl	548
4-(Trifluoromethyl)Phenyl	580
4-Chlorophenyl	546.4

R	MH ⁺
3,4-Difluorophenyl	548.41
2-thienyl	518.43
2-Bromophenyl	590/592

Structure	MH ⁺
	550.26
	552.35
	584.45
	517.42
	517.4
	550.38
	530.4
	530.4 *

Structure	MH+
	542.41
	546.37
	502.41
	548.4
	580.43
	513.41 **
	513.42 ***
	537.34
	518.28
	534.4

Structure	MH+
	514.08

The compounds marked were resolved on a chiral column, using the conditions shown below

* Column: Merck 50mm 20µm Chiralpak ASV No.ASV00SC-JG001 / Eluant: MeOH

5 ** Column: 20µm Merck 50mm Chiralpak AS No. ASV00SC-JG001 / Eluant : MeOH


*** Column: 20µm Merck 50mm Chiralpak AD No.AD00SC-HL001 / Eluant:

MeOH/MeCN 50/50

10

EXAMPLE 19

(1R or 1S)-1-[(4-[5-(2,4-difluorophenyl)pyrimid-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide




15

Racemate (250 mg, see example 18) was chromatogrammed (preparative Chiral-AS [Chiral Technologies Europe] HPLC column, eluted with 5% acetonitrile in methanol. Yield 71 mg.

20 Mass: ES+ (M+H)+ = 548)

EXAMPLE 20

The following compounds were prepared in an analogous manner to that given in Example 16 using the appropriate boronic acid in place of 4-fluorophenyl boronic acid:




R	MH+
2-Chlorophenyl	550/552
2-Fluorophenyl	534

5

EXAMPLE 21

1-[(4-[5-(2-Fluorophenyl) pyrimidin-2-yl] piperazin-1-yl) sulfonyl) methyl]-3-pyrimidin-2-ylpropyl (hydroxy)formamide.

10



Formic acid (3.2ml) and acetic anhydride (0.8ml) were mixed together at 0°C for 30 minutes, before being added to a crude solution of 5-(2-fluorophenyl)-2-(4-[(2-(hydroxyamino)-4-pyrimidin-2-ylbutyl)sulfonyl]piperazin-1-yl)pyrimidine (740mg) in tetrahydrofuran (15ml) at 0°C. The reaction was allowed to reach room temperature and was stirred overnight, evaporated to dryness and the residue was dissolved in methanol. The solution was stirred at 40°C for 3 hours and then evaporated to dryness to yield an oil. The oil was triturated with diethyl ether to yield 1-[(4-[5-(2-fluorophenyl) pyrimidin-2-yl] piperazin-1-yl) sulfonyl) methyl]-3-pyrimidin-2-ylpropyl (hydroxy)formamide as a white solid. Yield 580mg. 82% yield over 3 steps.

20

NMR (d6-DMSO@278k) δ 9.95 & 9.6, m, 1H; 8.65, s, 2H; 8.3 & 7.9, d, 1H; 7.7-7.5, m, 4H; 7.4, m, 1H; 7.25, m, 3H; 4.2 & 4.8, m, 1H; 3.8-4.0, m, 4H; 3.6-3.4, m, 1H; 3.3, m, 4H; 2.9, m, 2H; 2.1, br m, 2H.

5 MS MH⁺ 516

The starting material was prepared as follows:

ii) To 5-bromo-2-[4-(methylsulfonyl)piperazin-1-yl]pyrimidine [see example 16] (8.2g, 25.5mmol) suspended in anhydrous tetrahydrofuran (250ml), under nitrogen, cooled to between -60 and -65°C was added sequentially lithium bis(trimethylsilyl)amide (1.0M in
10 , tetrahydrofuran 51.0ml, 51mmol), with stirring for 20 minutes at -60°C, followed by diethyl chlorophosphonate (3.7ml, 25.5 mmol), with stirring for 20 minutes and then allowed to warm to -20°C before addition of a solution 3-pyrimidin-2-ylpropanal (3.2g, 23.0mmol) in anhydrous tetrahydrofuran (20ml). The mixture was stirred at -20°C for 1
15 hour, quenched with saturated ammonium chloride solution and allowed to warm to ambient temperature. The reaction mixture was diluted with water (100 ml) and ethyl acetate (100 ml), transferred to a separating funnel the aqueous wash separated and back extracted with ethyl acetate (2 X 100 ml). The combined organic extracts washed with saturated brine (150 ml), dried over magnesium sulphate. The ethyl acetate was removed in
20 vacuo to give 5-bromo-2-(4-{[(1*E*)-4-pyrimidin-2-ylbut-1-enyl]sulfonyl}piperazin-1-yl)pyrimidine as a white crystalline material isolated by triturating with ethanol (5.6g, 50% Yield).

MS: ES⁺, (M+H)⁺ = 440, 442 (Br isotope pattern)

25 NMR (d6-DMSO@278k) δ 8.7-8.6, m, 2H; 8.5, m, 2H; 7.4-7.2, m, 1H; 6.8-6.2, m, 2H; 3.8, m, 4H; 3.1, m, 4H; 2.9, m, 2H; 2.7, m, 2H;

(iii) 5-Bromo-2-(4-{[(1*E/Z*)-4-pyrimidin-2-ylbut-1-enyl]sulfonyl}piperazin-1-yl)pyrimidine (600mg) was dissolved in dimethoxymethane (40ml) under an argon
30 atmosphere. 2-fluorophenyl- boronic acid (154mg) and tetrakis(triphenylphosphine)palladium (132mg) were added, followed by saturated sodium

hydrogen carbonate solution (20ml). The reaction mixture was refluxed under argon for 2.5 hours, cooled and partitioned between ethyl acetate and water. The organic phase was collected, dried over magnesium sulphate, filtered and evaporated to dryness to yield the crude product 5-(2-fluorophenyl)-2-(4-{{(1*E/Z*)-4-pyrimidin-2-ylbut-1-enyl} sulfonyl} piperazin-1-yl) pyrimidine. The crude product (~750 mg) was used without further purification.

NMR (d6-DMSO@278k) δ 8.6, m, 2H; 7.5, m, 3H; 7.4-7.15, m, 4H; 6.8-6.4, m, 2H; 3.8, m, 4H; 3.05, m, 2H; 2.9, m, 4H; 2.7, m, 2H.

MS MH⁺ 455


(iv) The crude 5-(2-fluorophenyl)-2-(4-{{(1*E/Z*)-4-pyrimidin-2-ylbut-1-enyl}sulfonyl}piperazin-1-yl)pyrimidine (~750 mg) was dissolved in tetrahydrofuran (15ml) and hydroxylamine (50% in water) (10ml) was added. The mixture was stirred at ambient temperature overnight. Solvent was removed by evaporation and the residue was partitioned between ethyl acetate (50ml) and water (20ml), the aqueous wash back extracted with ethyl acetate (2X50ml). The organic phases combined, washed with brine (75 ml) and dried over magnesium sulphate, filtered and evaporated to dryness to give crude 5-(2-fluorophenyl)-2-(4-{{2-(hydroxyamino)-4-pyrimidin-2-ylbutyl}sulfonyl}piperazin-1-yl)pyrimidine. Yield 740mg.

NMR (d6-DMSO@278k) δ 8.6, m, 2H; 8.7, m, 2H; 7.7-7.5, m, 4H; 7.4, m, 1H; 7.25, m, 3H; 5.8, m, 1H; 3.8-4.0, m, 4H; 3.4, m, 1H; 3.3-2.9, m, 6H; 2.1-1.9, br m, 2H.

MS MH⁺ 488

EXAMPLE 22

The following compounds were prepared by the method given in Example 21 using the appropriate boronic acid in place of 2-fluorophenylboronic acid:




R	MH ⁺
2-Chlorophenyl	532
2,4-Difluorophenyl	534
3,5-Difluorophenyl	534
3-Pyridyl	499
4-Pyridyl	499

5

EXAMPLE 23

hydroxy[1-({[4-(5-pyridin-2-ylpyrimidin-2-yl)piperazin-1-yl]sulfonyl}methyl)-4-pyrimidin-2-ylbutyl]formamide

10



Formic acid (1.8 mL, 50 mmol) and acetic anhydride (0.45 mL, 5 mmol) were mixed together at 0°C for 30 minutes, before being added to a solution of 2-(4-{[2-(hydroxyamino)-5-pyrimidin-2-ylpentyl]sulfonyl}piperazin-1-yl)-5-pyridin-2-ylpyrimidine (crude from previous step) in tetrahydrofuran (5 mL) at 0°C. The reaction was allowed to reach room temperature and was stirred for 45 minutes. The reaction was then evaporated *in vacuo*, and azeotroped with toluene (2 x 5 mL). The residue was dissolved in MeOH and heated to 45°C for one hour. The solution was then evaporated *in vacuo*, and the residue was purified by flash chromatography (silica gel, 1% to 5% MeOH in CH₂Cl₂) to give hydroxy[1-({[4-(5-pyridin-2-ylpyrimidin-2-yl)piperazin-1-yl]sulfonyl}methyl)-4-pyrimidin-2-ylbutyl]formamide as a white solid (214 mg, 0.41 mmol 43% over 3 steps). NMR (d6-DMSO@373k) δ 9.40 (br, s, 1 H), 9.05 (s, 2 H), 8.68 (m, 3 H), 8.14 (br, s, 1 H), 7.85 (m, 2 H), 7.29 (m, 2H), 4.40 (vbr, s, 1 H), 3.95 (m, 4 H), 3.47 (dd, 1 H), 3.33 (m, 4 H), 3.19 (dd, 1 H), 2.90 (m, 2 H), 1.76 (m, 4H). MS (ESI): 513.51(MH⁺)

The starting material was prepared as follows :

To a stirred solution of *tert*-butyl 4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate (4.9 g, 14.3 mmol, CAS number 374930-88-8) 2-(tributylstannyl)pyridine (7.9 g, 21.45 mmol, CAS number 17997-47-6) in DMF (50 ml) was added tetraethylammonium chloride (2.36g, 14.3 mmol), potassium carbonate (1.98g, 14.3 mmol) and bis(triphenylphosphine)palladium(II) chloride (0.5 g, 0.71 mmol). The reaction was then stirred under an atmosphere of argon for 2 hours at 100°C before being cooled to RT. The reaction was filtered through a 0.45 μ m nylon filter and diluted with water (100 ml), extracted the aqueous with EtOAc (2x 50 ml) and the combined organic extracts were dried (MgSO₄), filtered and evaporated *in vacuo* . The residue was then purified by flash chromatography (90g Biotage silica gel cartridge, 10% to 40% EtOAc in hexanes) to give *tert*-butyl 4-(5-pyridin-2-ylpyrimidin-2-yl)piperazine-1-carboxylate as a white solid (1.40g, 4.1 mmol, 28%). NMR (CDCl₃) δ 8.95 (s, 2 H), 8.64 (d, 1 H), 7.73 (m, 1 H), 7.59 (d, 1 H), 7.20 (m, 1 H), 3.90 (m, 4 H), 3.52 (m, 4 H), 1.49 (s, 9 H).

MS (ESI): 286.02 ($\text{MH}^+ - t\text{-Bu}$)

To a stirred solution of *tert*-butyl 4-(5-pyridin-2-ylpyrimidin-2-yl)piperazine-1-carboxylate (1.39 g, 4.1 mmol) in CH_2Cl_2 (20 mL) at RT was added trifluoroacetic acid (4 mL). The mixture was then stirred vigorously at RT for 1 hour. Volatiles were removed *in vacuo*, and the residue was azeotroped with toluene (3 x 10 mL).

The crude residue was then dissolved in CH_2Cl_2 (20 mL) and cooled to 0°C. Triethylamine (1.7 mL, 12.3 mmol) was then added, followed by dropwise addition of methanesulfonyl chloride (0.35 mL, 4.5 mmol). The reaction was then allowed to stir at RT for one hour, before being quenched by the addition of water (10 mL). The layers were separated, and the aqueous phase extracted with CH_2Cl_2 (2 x 10 mL). The combined organic extracts were dried (MgSO_4), filtered and evaporated *in vacuo* to give a yellow gum which was stirred with ethanol and filtered to give 2-[4-(methanesulfonyl)piperazin-1-yl]-5-pyridin-2-ylpyrimidine as a white solid (0.61 g, 47%).

^1H NMR ($\text{d}_6\text{-DMSO}$) δ : 9.18 (s, 2 H), 8.63 (d, 1 H), 7.93 (d, 1 H), 7.87 (m, 1 H), 7.31 (m, 1 H), 3.93 (m, 4 H), 3.20 (m, 4 H), 2.89 (s, 3 H).

MS (ESI): 320.33 (MH^+)

To a stirred suspension of 2-[4-(methanesulfonyl)piperazin-1-yl]-5-pyridin-2-ylpyrimidine (300 mg, 0.94 mmol) in THF (10 mL) at -10°C, was added dropwise a solution of LiHMDS in THF (1.9 mL, 1.0M solution, 1.9 mmol). The resulting suspension was stirred at -10°C for 30 minutes before being treated with diethyl chlorophosphate (0.135 mL, 0.94 mmol). The solution was then maintained at -10°C and then treated with a solution of 4-pyrimidin-2-ylbutanal (155 mg, 1.04 mmol) in THF (1 mL). The solution was then maintained at -10 °C for 30 minutes before being quenched with saturated aqueous ammonium chloride solution (5 mL). The layers were separated and the aqueous phase extracted with ethyl acetate (2 x 5 mL). The combined organic extracts were then dried, (MgSO_4), filtered and concentrated *in vacuo* to give 5-pyridin-2-yl-2-(4-[(1*E*/*Z*)-5-pyrimidin-2-ylpent-1-enyl]sulfonyl)piperazin-1-yl)pyrimidine as a cream solid which was used crude in the next step.


MS (ESI): 452.0 (MH^+)

To a stirred solution of 5-pyridin-2-yl-2-(4-{{[(1*E*/*Z*)-5-pyrimidin-2-ylpent-1-enyl]sulfonyl}piperazin-1-yl}pyrimidine (crude from previous step) in THF (5 mL) at RT
5 was added 50% aqueous hydroxylamine (1.0 mL) and the mixture stirred rapidly for 2 hours. The reaction was quenched by the addition of saturated ammonium chloride solution (5 mL) and the layers were then separated. The aqueous phase was extracted with EtOAc (2 x 5 mL) and the combined organic extracts were then dried ($MgSO_4$), filtered and evaporated *in vacuo* to give 2-(4-{{[2-(hydroxyamino)-5-pyrimidin-2-ylpentyl]sulfonyl}piperazin-1-yl}-5-pyridin-2-ylpyrimidine as a white solid which was
10 used crude in the next step.

MS (ESI): 485.49 (MH^+)

EXAMPLE 24

15 **3-(5-fluoropyrimidin-2-yl)-1-({[4-(5-pyridin-2-ylpyrimidin-2-yl)piperazin-1-yl]sulfonyl}methyl)propyl(hydroxy)formamide**




The title compound was prepared using an analogous method to that given in example 23 --
20 replacing 4-pyrimidin-2-ylbutanal by 3-(5-fluoro-pyrimidin-2-yl)propanal.

MH^+ 517.44

CLAIMS:

What we claim is:

1. A compound of the formula I or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof



wherein

A and B are each independently selected from phenyl and up to C6 heteroaryl;

at least one of A and B is heteroaryl;

n1 and n2 are each independently selected from 0, 1, 2, 3;

each R2 and each R3 is independently selected from OH, NO₂, CF₃, CN, halogen, SC₁₋₄alkyl, SOC₁₋₄alkyl, SO₂C₁₋₄alkyl, C₁₋₄alkyl, C₁₋₄alkoxy;

M₁ is selected from N and C;

R1 is the group -X-Y;


X is C₁₋₆alkyl;

Y is selected from up to C10 cycloalkyl, up to C10 aryl, and up to C10 heteroaryl;

Y is optionally substituted by up to three groups independently selected from OH, NO₂, CF₃, CN, halogen, SC₁₋₄alkyl, SOC₁₋₄alkyl, SO₂C₁₋₄alkyl, C₁₋₄alkyl, C₁₋₄alkoxy;

Z is selected from -N(OH)CHO, and -C(O)NHOH.

2. A compound of the formula II or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof



wherein

A and **B** are each independently selected from phenyl and up to C6 heteroaryl;
at least one of **A** and **B** is heteroaryl;

n1 and **n2** are each independently selected from 0, 1, 2, 3;

each **R2** and each **R3** is independently selected from OH, NO₂, CF₃, CN, halogen, SC₁₋₄alkyl, SOC₁₋₄alkyl, SO₂C₁₋₄alkyl, C₁₋₄alkyl, C₁₋₄alkoxy;

M1 is selected from N and C;

R1 is the group -X-Y;

X is C₁₋₆alkyl;

Y is selected from up to C10 cycloalkyl, up to C10 aryl, and up to C10 heteroaryl;

Y is optionally substituted by up to three groups independently selected from OH, NO₂, CF₃, CN, halogen, SC₁₋₄alkyl, SOC₁₋₄alkyl, SO₂C₁₋₄alkyl, C₁₋₄alkyl, C₁₋₄alkoxy.

3. A compound as claimed in claim 1 or claim 2 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof wherein at least one of **A** and **B** is a five- or six-membered aromatic ring containing one or more heteroatoms independently selected from N, O, S.

4. A compound as claimed in claim 3 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof wherein at least one of **A** and **B** is pyridyl, pyrimidinyl, thienyl, or furyl.

5. A compound as claimed in claim 1 or claim 2 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof wherein **B** is not substituted or **B** is substituted by at least one **R2** group selected from CF₃, CN, halogen, C₁₋₄alkyl.

6. A compound as claimed in claim 1 or claim 2 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof wherein **A** is not substituted or **A** is substituted by at least one **R3** group selected from CF₃, CN, halogen, C₁₋₄alkyl.

7. A compound as claimed in claim 1 or claim 2 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof wherein **M₁** is N.

8. A compound as claimed in claim 1 or claim 2 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof wherein **X** is C₂₋₅alkyl.

9. A compound as claimed in claim 8 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof wherein **X** is C₂₋₃alkyl.

10. A compound as claimed in claim 1 or claim 2 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof wherein **Y** is selected from phenyl and a five- or six-membered aromatic ring containing one or more heteroatoms independently selected from N, O, S.

11. A compound as claimed in claim 10 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof wherein **Y** is selected from phenyl, pyridyl, pyrimidinyl, or pyrazinyl.

12. A compound as claimed in claim 1 or claim 2 or claim 10 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof wherein **Y** is not substituted or **Y** is substituted by at least one group independently selected from halogen, CF₃, and MeO.

13. A compound as claimed in claim 12 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof wherein **Y** is not substituted or **Y** is substituted by at least one halogen group.

14. A compound of the formula I as claimed in claim 1 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof wherein the compound of the formula I is as exemplified herein.

- 5 15. A compound as claimed in claim 14 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof wherein the compound is selected from Hydroxy[4-pyrimidin-2-yl-1-({[4-(4-thien-3-ylphenyl)piperazin-1-yl]sulfonyl}methyl)butyl]formamide, 1-[(4-[5-(4-fluorophenyl)pyridin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide, 1-[(4-[5-(4-chlorophenyl)pyridin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide, 1-[(4-[5-(3-furyl)pyridin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide, 1-[(4-[5-(2-furyl)pyridin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide, 1-[(4-(2,3'-bipyridin-6'-yl)piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide, hydroxy[4-pyrimidin-2-yl-1-({[4-(5-thien-2-ylpyridin-2-yl)piperazin-1-yl]sulfonyl}methyl)butyl]formamide, 1-[(4-[5-(2-furyl)pyridin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide, 1-[(4-[5-(4-fluorophenyl)pyrazin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide, hydroxy[1-({[4-(5-phenylpyrazin-2-yl)piperazin-1-yl]sulfonyl}methyl)-4-pyrimidin-2-ylbutyl]formamide, 1-[(4-[5-(3-furyl)pyridin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide, 1-[(4-[5-(4-fluorophenyl)pyrimidin-2-yl]piperazin-1-yl)sulfonyl)methyl]-3-pyrimidin-2-ylpropyl(hydroxy)formamide, (1*S*)-1-[(4-[5-(4-fluorophenyl)pyrimidin-2-yl]piperazin-1-yl)sulfonyl)methyl]-3-pyrimidin-2-ylpropyl(hydroxy)formamide, (1*S*)-1-[(4-[5-(4-fluorophenyl)pyrimidin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide, 1-[(4-[5-(2-chloro-4-fluorophenyl)pyrimidin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide, (1*R* or 1*S*)-1-[(4-[5-(2,4-difluorophenyl)pyrimidin-2-yl]piperazin-1-yl)sulfonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide, 1-[(4-[5-(2-Fluorophenyl)pyrimidin-2-yl]piperazin-1-yl)sulfonyl)methyl]-3-pyrimidin-2-ylpropyl(hydroxy)formamide, hydroxy[1-({[4-(5-pyridin-2-ylpyrimidin-2-yl)piperazin-1-yl]sulfonyl}methyl)-4-pyrimidin-2-ylbutyl]formamide, and 3-(5-fluoropyrimidin-2-yl)-1-
- 10
- 15
- 20
- 25
- 30

{{[4-(5-pyridin-2-ylpyrimidin-2-yl)piperazin-1-yl]sulfonyl}methyl)propyl(hydroxy)formamide.

5 16. A pharmaceutical composition which comprises a compound of the formula I as claimed in claim 1 or a compound of the formula II as claimed in claim 2 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof and a pharmaceutically acceptable carrier.

10 17. A compound of the formula I as claimed in claim 1 or a compound of the formula II as claimed in claim 2 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for use in a method of therapeutic treatment of the human or animal body.

15 18. A compound of the formula I as claimed in claim 1 or a compound of the formula II as claimed in claim 2 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for use as a therapeutic agent.

20 19. A method of treating a metalloproteinase mediated disease condition which comprises administering to a warm-blooded animal a therapeutically effective amount of a compound of the formula I as claimed in claim 1 or a compound of the formula II as claimed in claim 2 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.

25 20. A method of treating a metalloproteinase mediated disease condition as claimed in claim 19 which comprises treating a disease condition mediated by MMP13.

30 21. The use of a compound of the formula I as claimed in claim 1 or a compound of the formula II as claimed in claim 2 or a pharmaceutically acceptable salt or in vivo hydrolysable precursor thereof in the preparation of a medicament for use in the treatment of a disease condition mediated by one or more metalloproteinase enzymes.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/01437

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 239/42, C07D 403/14, C07D 409/12, C07D 401/12, C07D 405/12,
C07D 405/14, C07D 401/14, C07D 409/14, C07D 401/14, A61K 31/506, A61P 19/02
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEM.ABS.DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 0012478 A1 (ZENECA LIMITED), 9 March 2000 (09.03.00) --	1-22
X	US 6100266 A (MONTANA ET AL), 8 August 2000 (08.08.00) --	1-22
P,X	WO 0187870 A1 (DARWIN DISCOVERY LIMITED), 22 November 2001 (22.11.01) --	1-22
P,X	WO 0162742 A1 (ASTRAZENECA AB), 30 August 2001 (30.08.01) --	1-22

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

22 November 2002

Date of mailing of the international search report

26-11-2002

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

SOLVEIG GUSTAVSSON/BS

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/01437

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 0162751 A1 (ASTRAZENECA UK LIMITED), 30 August 2001 (30.08.01) -- -----	1-22

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE02/01437

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **19-20**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Claims 19-20 relate to methods of treatment of the human or animal body by surgery or by therapy/diagnostic methods practised on the human or animal body/Rule. 39.1.(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT

Information on patent family members

28/10/02

International application No.

PCT/SE 02/01437

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	0012478	A1	09/03/00	AU	5524799 A	21/03/00
				BG	105369 A	31/12/01
				BR	9913255 A	22/05/01
				CA	2339761 A	09/03/00
				CN	1324347 T	28/11/01
				EE	200100106 A	17/06/02
				EP	1109787 A	27/06/01
				GB	9919776 D	00/00/00
				HU	0103344 A	28/02/02
				JP	2002523493 T	30/07/02
				NO	20011023 A	25/04/01
				PL	346344 A	11/02/02
				SK	2702001 A	06/08/01
				TR	200100605 T	00/00/00
US	6100266	A	08/08/00	AU	2291499 A	16/08/99
				BR	9908215 A	28/11/00
				EP	1051395 A	15/11/00
				GB	9802073 D	00/00/00
				GB	9819574 D	00/00/00
				NO	20003868 A	28/07/00
				WO	9938843 A	05/08/99
				AU	735929 B	19/07/01
				AU	739466 B	11/10/01
				AU	8349498 A	10/02/99
				BR	9811004 A	19/09/00
				CA	2317455 A	05/08/99
				CN	1289322 T	28/03/01
				EP	0996445 A	03/05/00
				HU	0002643 A	28/10/01
				HU	0100597 A	28/08/01
				IL	133908 D	00/00/00
				IL	137146 D	00/00/00
				JP	2001510155 T	31/07/01
				JP	2002501943 T	22/01/02
				NO	20000169 A	13/01/00
				NZ	502201 A	21/12/01
				PL	337996 A	25/09/00
				PL	342184 A	21/05/01
				US	6372763 B	16/04/02
				ZA	9900731 A	31/01/00
WO	0187870	A1	22/11/01	AU	5854001 A	26/11/01
				GB	0011721 D	00/00/00
				US	2002037900 A	28/03/02
				GB	0029393 D	00/00/00
WO	0162742	A1	30/08/01	AU	3385501 A	03/09/01
				US	2002022628 A	21/02/02
WO	0162751	A1	30/08/01	AU	3385401 A	03/09/01